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”HAVET BLIR STÖRRE AV EN ENDA DROPPE”

  
1 ABSTRACT 
 
The lethal disease infective endocarditis (IE) is caused by microorganisms that attack heart 
valves. Early diagnosis and identification of the causative agents are important for the choice 
of treatment. Optimal treatment may be difficult to achieve if blood culture negative 
endocarditis (CNE) is present. This study was designed to estimate the prevalence of CNE, 
analyze clinical data from CNE patients, and to evaluate different diagnostic criteria. Further 
purposes were to evaluate the antibiotics used as treatment, to study serological evidence for 
fastidious bacterial infection and to assess the association of Chlamydophila pneumoniae (C. 
pneumoniae) antibodies with an increased risk of development for IE.  
We analyzed data from presumptive IE patients in clinics at Borås (n=70) (Paper I) and 
Göteborg (n= 750) (Paper I, II, III) and at the Swedish Endocarditis registry (n=2509) (Paper 
IV).  Serum samples from Göteborg IE patients were tested for the presence of Bartonella, 
Coxiella burnetii and C. pneumoniae antibodies.  Samples from controls selected from the 
same geographic population were searched for antibodies to C. pneumoniae.  
Twelve to 27% of all IE episodes were CNE with a mortality of 5-7 %. Antibiotic treatment 
preceded blood culturing in 45% of the episodes. Women died significantly more often than 
men with this disease (odds ratio 5.5). For establishing IE diagnosis, the Duke definite 
criteria were more sensitive but probably less specific than the Beth Israel criteria. 
One patient had serologically verified Q-fever IE, but no Bartonella was detected.  The 
proportion of C. pneumoniae antibodies did not differ significantly in patients with CNE from 
those with blood culture positive IE. However amounts of C. pneumoniae IgA and IgG were 
significantly higher in women with IE than in the female controls.  
The mortality rate was significantly lower in CNE patients treated with aminoglycosides.  
CNE occurred in 12-27% of IE patients reviewed here, but antibiotic treatment preceding 
blood culture diminished the validity of negative test results.  Fastidious bacteria were 
identified mainly by testing with antibodies, yet interpretations of such results are difficult. 
Clearly, additional methods are needed for diagnosing CNE.  
Key words: Infective endocarditis (IE), blood culture negative endocarditis (CNE), blood 
culture, diagnosis, mortality, Bartonella, Coxiella burnetii, Chlamydophila pneumoniae, 
prevalence, aminoglycoside. 
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LIST OF ABBREVIATIONS 
 
aOR Adjusted odds ratio 
CNE Blood culture negative endocarditis  
CPE Blood culture positive endocarditis 
FAN  
 
Aerobic and anaerobic media composed of brain heart infusion broth and 
Ecosorb (contains absorbent charcoal and Fullers earth) 
HACEK Hemophilus spp, Actinobacillus acinetocomitans, Cardiobacterium 
hominis, Eikinella, Kingella kingae 
ICD-9 International Statistical Classification of Diseases, Ninth revision 
IE Infective endocarditis 
IVDU  Intravenous drug user 
MIF Microimmunofluorescence 
NBTE Nonbacterial thrombotic endocarditis 
NVE Native valve endocarditis 
OR Odds ratio 
PCR Polymerase chain reaction 
PPV Positive predictive value 
PVE Prosthetic heart valve endocarditis 
RF Rheumatoid factor 
TEE Transesophageal echocardiography 
TTE Transthoracal echocardiography 
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2 INFECTIVE ENDOCARDITIS (IE) 
 
IE can result when microorganisms (bacteria and fungi) in the blood infect the heart 
valve(s) and form a vegetative growth consisting mainly of fibrin, platelets and the 
microorganisms. These vegetation constituents may embolize to such organs as the 
brain, skin, lung, central nervous system and kidney causing diverging symptoms. The 
bacteremia may cause septic symptoms. IE is lethal if not adequately treated. The 
incidence in Sweden of IE has been estimated at 5.9 /100,000 yearly (1). In spite of 
improved methods in blood culturing and echocardiography, and the introduction of 
increasingly accurate diagnostic criteria, IE is still difficult to diagnose (2, 3). 
Additionally, the diversified symptoms may attract the clinician’s attention to other 
potential diseases including stroke, pneumonia, heart insufficiency, pulmonary 
embolism, meningitis, nephritis, urinary infection or collagenosis.  
 
 
2.1 BLOOD CULTURE NEGATIVE ENDOCARDITIS (CNE) 
 
Positive blood cultures are corner stones in diagnosing IE. However, CNE has been 
reported during recent decades in population-based epidemiological studies as well as 
hospital studies world wide ranging from 5 to 56% of all cases of IE (1, 4-13). When 
estimating the proportions of CNE, factors such as diagnostic criteria, demographic 
information, environmental factors and the health care structure must be considered. 
Numerous other factors may contribute to CNE such as antibiotic therapy started 
before blood culture (6, 11, 14, 15) and the presence of fastidious bacteria, for 
example Bartonella, Coxiella, Legionella pneumophila (16) and Tropheryma 
whipplei (17) all of which need  diagnostic techniques other than blood culture. 
Nonbacterial thrombotic endocarditis (NBTE) in patients with cancer or autoimmune 
disease and hypercoagulability (18-20) is  also  a major reason for CNE. 
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2.2 CULTURE, HISTOLOGY AND MOLECULAR GENETIC METHODS  
 
2.2.1 Blood culture 
 
In the 1880s blood culturing in clinical practice was initiated by the French physician 
Jacques Dolores (21), advised by Louis Pasteur, who was the first to perform this 
procedure.  The blood was collected by a pinprick on the index finger with a sterile 
technique. At that time, however, microbiologists had not overcome the technical 
problems of blood culturing and were not aware that the amount of blood from a 
pinprick provided too small a sample for culturing.  
 
The modern microbiological laboratory uses automated systems analyzing 20 ml of 
blood from every puncture. The optimal volume for detecting the small concentration 
of bacteria in patients with IE has been estimated at three 20 ml samples of blood (60 
ml) drawn before the initiation of antibiotic therapy (22-24). If no bacterial growth 
occurs, blood cultures from IE patients often are incubated for a longer period than the 
usual 7 to10 days in an attempt to detect bacteria from the Hemophilus spp, Actino-
bacillus acinetocomitans, Cardiobacterium hominis, Eikinella, Kingella kingae 
(HACEK) group. However, recent studies have shown that prolonged incubation is no 
more sensitive for detecting these bacteria than the routine five days of incubation (25-
27).The molecular genetic methods such as polymerase chain reaction (PCR) for 
detecting bacteria in blood are still not reliable in clinical practice (28).  
 
2.2.2 Valvular culture, histology and molecular genetic methods 
 
When diagnosing IE (2, 3), examination of the heart valve is considered as the gold 
standard. If present, pathogens can be identified in resected valves from IE patients 
with culture including Gram stain (29),  histologic methods including histochemistry 
(30) and / or molecular genetic methods such as PCR (31-33). These procedures are 
often successful in identifying microorganisms in vegetations because of their large 
concentration. However, valvular culture has low sensitivity (13%) (32), (15%) (34), 
low negative predictive value for detecting microorganisms (56%) (32) and low 
specificity (35). Cultures may also have false-positive outcomes due to contamination 
of the resected valves at surgery (35). Regardless of the testing procedure(s) used, 
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making a clinical diagnosis that IE is or is not present during operative valve resection 
is important. Microorganisms detected in valves by PCR and histopathology may have 
persisted at that site months after the full recovery from IE (29, 36-38).   
 
 
2.3 FASTIDIOUS BACTERIA IN CNE 
 
2.3.1 Bartonella 
 
Bartonella quintana causes trench fever, a five-day relapsing fever accompanied by 
severe pain in the shins.  Although seldom fatal, this condition disables patients for a 
long time. Humans are the only proven reservoirs of the bacterium (39), and the body 
louse is the vector of the disease. Trench fever was endemic amongst the troops on all 
European fronts during World War I, then re-emerged as an epidemic disease mainly at 
the Eastern front during World War II (40). The last Swedish patient known to contract 
this disease was a farmer from Northern Sweden in close contact with Finnish refugees 
during World War II (41). 
 
Trench fever emerged anew as CNE in homeless persons at the end of the 20th century 
in France (42) and North America (43)  with B. quintana being isolated from these 
patients. Bacillary angiomatosis caused by B. quintana has been described in 
immunocompromised hosts (44). Moreover, antibodies to B. quintana have been found 
amongst homeless people in France (45). 
 
Bartonella henselae causes cat-scratch disease, which is characterized by a skin lesion 
after a cat-scratch or cat-bite and regional lymphadenopathy. B. henselae has been 
found in patients with CNE , bacillary angiomatosis or peliosis hepatitis in 
immunocompromised hosts (46). The reservoir of this disease is probably the cat.  The 
infection is spread directly from cat to human or indirectly via a vector, probably the 
cat flea (Ctenocephalides felis) (47). Sometimes Bartonella is detected in cultured 
blood when the incubation time is prolonged, but other diagnostic methods are more 
reliable such as the shell-vial technique (48), molecular methods or serology (26, 49). 
 A genotypic variation of B. henselae, serotype “Marseille” has been isolated from 
patients with endocarditis and cat-scratch disease. Antibodies to this serotype have been 
shown in patients with cat-scratch disease who were seronegative to B. henselae (50, 
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51). At the start of our study, no cases of Bartonella endocarditis had been reported in 
Sweden. 
 
2.3.2 Coxiella burnetii (C. burnetii) 
 
Q-fever, a rickettsiosis caused by C. burnetii, is a zoonosis diagnosed worldwide. The 
bacterium is usually transmitted as an inhaled aerosol that reaches humans via 
inhalation of parturient fluid from infected animals. The bacteria can survive for long 
periods in areas where animals have been present and even the wind can transmit this 
infection to humans. Endocarditis is the most severe form of chronic Q-fever 
sometimes recognized in CNE patients. Patients with recurrent CNE in prosthetic 
valves may have chronic Q-fever (52). In Sweden sporadic cases of domestic Q-fever 
have been reported (53) but not in relation to IE. However, seroepidemiological studies 
from all over the country have revealed antibodies to C. burnetii (54, 55).  This 
infection is diagnosed preferably with serology although valve culture, histopathology 
and molecular methods also detect C. burnetii. 
 
2.3.3 Chlamydophila (Chlamydia) pneumoniae (C. pneumoniae) 
 
Although C. pneumoniae has been described as an agent of CNE (56, 57), its role in IE 
remains debatable, because Bartonella and C. pneumoniae cross-react serologically. In 
addition, an association between C. pneumoniae and arteriosclerosis as well as valvular 
disease has been suggested (58-65). No validated reference test is universally agreed 
upon for the diagnosis of persistent C. pneumoniae infection.  The microimmuno-
fluorescence (MIF) test, considered to be the gold standard, is technically complex and 
diagnostic criteria can differ from laboratory to laboratory (66). 
 
One can expect to detect IgG antibodies in serum for many years after an infection, and 
serum IgG of ≥512 may indicate either a possible chronic infection or a recent infection 
with the bacterium. IgA antibodies have a short half-life (about one week); therefore, 
high levels of this immunoglobulin more likely denote an acute or sustained infection, 
although this criterion is not a universally accepted (66). Tissue cell culture, molecular 
methods and histochemistry also detect C. pneumoniae. 
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2.4 ECHOCARDIOGRAPHY 
 
After its invention in the 1970s, echocardiography was quickly introduced into medical 
practice to investigate suspected cases of IE (67). The first study of this method’s 
impact in diagnosing CNE was published in 1981 (68). Transthoracal echocardio-
graphy (TTE) based on sound transmission through the thoracic wall may allow 
visualization of vegetations and heart function. The subsequent development of 
transesophageal echocardiography (TEE) with the sound-emitting probe in the 
esophagus closer to the heart improved such transmissions substantially. With its higher 
sensitivity TEE detects small vegetations, infection of prosthetic heart valves, infected 
pacemaker leads and perivalvular abscesses. However, TTE has improved with the 
second harmonic imaging (69-71). TEE is a cost-effective investigative tool (72) if the 
prior probability of IE is high. In a retrospective study, however, TTE was not effective 
in screening patients with little likelihood of having IE (73). 
 
 
2.5 DIAGNOSTIC CRITERIA 
 
IE is a difficult disease to diagnose because of its diverse manifestations. The Beth 
Israel criteria (3), introduced in 1981, were the first established guidelines for 
diagnosing IE on strictly defined clinical grounds. The introduction of 
echocardiography made it possible to visualize the heart, which was positive as a 
method was needed to enhance the diagnostic power for IE. Echocardiographic 
findings were added to the Beth Israel criteria in, for example, Göteborg, Sweden and 
France (modified Beth Israel criteria) (1, 5). The Duke criteria (2) published in 1994 
combined  echocardiographic findings with clinical criteria and are now established 
diagnosing IE. Numerous studies have compared the Beth Israel criteria (not 
modified) and Duke criteria in different settings (74-76), and most  judge the Duke 
criteria as the more sensitive of the two. Li and coworkers revised the Duke criteria in 
the year 2000 (77).  
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2.6 ANTIBIOTIC THERAPY IN CNE 
 
Treatment for CNE is difficult, and studies about antibiotic treatment for such patients 
are virtually nonexistent. The specialized diagnostic procedures described above are 
often time-consuming. Furthermore, the necessity of treating these patients with 
potentially harmful drugs such as aminoglycoside and the lack of knowledge about 
which microorganism to treat are frustrating for the responsible clinician. The Swedish 
Guidelines for IE (78) recommend the continuation of empiric therapy:  for native 
valve endocarditis (NVE),  penicillin-G for four weeks and aminoglycoside for two 
weeks and  for PVE (prosthetic valve endocarditis), vancomycin,  aminoglycoside and 
rifampicin for four to six weeks. The difficulties in treating CNE are also mirrored in 
the newly published consensus documents about IE from the US (79) and Europe (80). 
There are treatment suggestions for Bartonella IE (79) and chronic Q-fever (81), but 
comparative studies  for treatment regimens in these diseases are missing . 
No specific information about CNE in Sweden was available at the start of the present 
study; however, access to data registries for IE and collections of sera from IE patients 
gave us an opportunity to investigate this rare condition. 
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THE OBJECTIVES OF THE STUDY     
 
1. Describe and analyze clinical data from CNE patients and estimate the 
prevalence of CNE in IE episodes (Papers I and IV). 
2. Evaluate the Duke and the modified Beth Israel criteria in CNE patients. 
(Paper I). 
3. Describe the antibiotic treatments used in CNE patients related to mortality 
and relapse in IE (Paper IV). 
4.  Analyze serological signs of Bartonella, C. burnetii or C. pneumoniae 
infection associated with CNE (Papers II and III).  
5. Compare the assessed levels of C. pneumoniae antibodies in male and 
female IE with controls from the general population (Paper III).  
 8 
3 PATIENTS AND METHODS 
 
3.1 STUDY DESIGN 
 
3.1.1 Paper I 
 
To assess the incidence and characteristics of CNE in patients with IE, individuals 
(adults >18 years) were recruited at the Department of Infectious Diseases, Göteborg, 
Sweden between 1984 and 1996 and Department of Infectious Diseases, Borås, 
Sweden from 1989 to 1996.  
 
For the purposes of this program, the term “episode” was defined as a hospital 
admission for the treatment of IE. Two hundred and thirty-three episodes of 
presumptive IE (217 patients) were prospectively and consecutively studied at the 
Göteborg clinic during 1984-88. One hundred and sixty-one of these episodes were 
diagnosed as apparent IE. For 517 episodes of suspected IE, 460 patients were 
recruited in Göteborg between 1989 and 1996. Of these, 145 episodes were classified 
according to the Duke criteria (2) as “definite,” 111 as “possible” and 261 as 
“rejects.” Antibiotic combination therapy started in 363 of the 517 episodes. Records 
of 237 episodes in patients discharged with a diagnosis classified as IE (ICD-9) at the 
Göteborg clinic, from 1989 through 1996, were also evaluated to seek CNE patients 
not registered in the prospective study. At Borås an IE diagnosis (ICD-9), was found 
in a patient group that included 70 episodes. 
 
The information derived was used for a non-randomized descriptive study of 
consecutive patients with CNE treated as IE according to a protocol that included 
uniform antibiotic regimens, clinical evaluation procedures and the collection of 
specimens including blood cultures. 
 
Routinely, patients underwent echocardiography during the first week of treatment and, 
if indicated, repeated at the fourth week. The location of IE was determined by surgery, 
autopsy or echocardiography. 
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Patients’ demographic data, histories of suspected risk factors and other relevant events 
were extracted from records and registered in a standardized questionnaire. All CNE 
episodes were evaluated with the modified Beth Israel criteria (1) (Table 1).  We 
categorized the CNE episodes according to the Duke criteria (Tables 2 and 3). 
3.1.2 Paper II  
 
Seven hundred and fifty episodes were considered as presumptive IE in the Göteborg 
clinic during the years 1984 to 1996 (Paper I). These patients’ blood samples were 
collected at inclusion into the study, and sera were stored at -70°C. Sera from patients 
initially included in the study between 1984-1988 but later classified as “rejects” 
according to the modified Beth Israel criteria for IE were discarded (1). Some other 
samples were destroyed during storage. Finally, the 334 remaining sera from 334 
episodes in 329 patients were examined. All records from these IE episodes were 
evaluated and classified according to the Duke criteria.   
 
3.1.3 Paper III 
 
Patient selection and blood sampling were done in the same manner as described in 
Paper II.  Here, data for 314 episodes in 308 patients were analyzed for IE according to 
the Duke criteria and categorized as ”definite,” ”possible” or ”reject (2). Results from 
the 27 episodes classified as ”reject” were excluded from further analysis. Serum 
samples were taken at the start of IE therapy from all but four patients.   
 
The Longitudinal Gerontological and Geriatric Studies in Göteborg, Sweden, initiated 
in 1971/72 included 1148 70-year-old men and women who were randomly chosen 
from the same geographic population without regard of their state of health (82). The 
controls were a random sample from this group, which comprised of 102 men and 142 
women whose sera were analyzed for C. pneumoniae antibodies. In 1992, another 
randomly selected sample of 753 70-year-olds was added to the study, and sera samples 
from 76 men and 106 women in this second group were also analyzed for C. 
pneumoniae antibodies (83).  
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3.1.4 Paper IV 
 
During the ten-year period 1995-2004, 2546 episodes of IE were registered in a 
national Swedish registry (84) organized by the Swedish Society for Infectious 
Diseases. All 29 departments of infectious diseases in Swedish hospitals participated. 
For the present study, 37 episodes listed in this registry were excluded because of 
duplication, scarcity of data, lack of blood cultures or rejection by the Duke criteria.  
Data incorporated into this paper came from the remaining 2509 episodes (2410 
patients). 
 
Data were filled in standardized questionnaires that each patient’s physician 
completed at the time of his or her hospital discharge. The form included questions 
about the patient’s age, gender, clinical signs and predisposing factors for IE. Also 
required were data about the current episode of IE. At the follow-up visit, the 
physician filled in a second form answering questions about morbidity and mortality. 
The doctors treated their patients in accordance with local recommendations. The 
“Guidelines in Infective Endocarditis from The Swedish Society of Infectious 
Diseases” (78) included recommendations from 2004 regarding therapy  for CNE.  
 
Data from the questionnaires were entered into a computerized database and 
categorized according to the Duke criteria (2).  Our analyses then answered questions 
about demography, predisposing factors, treatment and outcome. 
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FIGURE 1.  Shows the division between studies I, II, III and IV.
Paper I
70 episodes
1989-96 Borås
Paper I
820 episodes
1984-96 Borås and Göteborg
Paper I
15 episodes
1989-96 Göteborg
Paper II
334 episodes
1984-96 Göteborg
Paper III
314 episodes
1984-96 Göteborg
Paper IV
2509 episodes
1995-2004 Sweden
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3.2 METHODS 
 
3.2.1 Definitions 
 
We defined  
• An episode as an admission to hospital for treatment of IE, regardless of the 
time interval since any previous episode and the first day of an episode as the 
first day of intravenous antibiotic combination treatment. 
• CNE as IE without bacterial growth in blood culture. 
• Mortality during treatment as death during parenteral antibiotic therapy 
calculated in episodes and  
o within the first month after completed treatment (Paper I)  
or 
o registered in questionnaire one (Paper IV).  
• Possible relapse of IE as a new event of IE during the six months after 
completed IE treatment. 
• Acute surgery as cardiac surgery performed during the period of parenteral 
antibiotic treatment. 
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3.2.2 Diagnostic criteria 
 
 The modified Beth Israel criteria (1, 3), and Duke criteria (2) were applied in Paper I. 
(Tables 1, 2 and 3) 
 
TABLE 1. Modified Beth Israel criteria (1, 3), further modified (only patients without 
bacterial growth at blood culture were accepted as culture negative). 
Definite infective endocarditis.  
Episodes in patients from whom the diagnosis was verified at surgery or autopsy by 
culture, microscopy 
Probable infective endocarditis.  
At least 2/3 positive blood cultures and one of the following factors characterize 
culture-positive endocarditis: A new cardiac murmur, predisposing heart disease1 with 
vascular phenomena2 and/or sonographic evidence of vegetation.  
Culture-negative endocarditis is characterized by negative blood cultures plus 
fever, new cardiac murmur and vascular phenomena2 or sonographic evidence 
of vegetation 
Possible infective endocarditis. 
Culture-positive endocarditis is characterized by at least 2/3 positive blood cultures 
and one of the following: Predisposing heart disease 1 and /or vascular phenomena 2  
Culture-negative endocarditis is characterized by negative blood cultures and 
all of the following: Fever, predisposing heart disease1 and vascular 
phenomena 2 alternatively sonographic evidence of vegetation 
Rejected 
(A). Endocarditis unlikely, alternative diagnosis generally apparent 
(B). Endocarditis likely, empirical antibiotic therapy warranted 
(C).Culture-negative endocarditis diagnosed clinically, but excluded by postmortem 
examination 
1 Valvular or congenital heart disease or valvular prosthesis.  
2 Petechiae, splinter hemorrhages conjunctival hemorrhages, Roth spots, Osler’s nodes, Janeway 
lesions, aseptic meningitis, glomerulonephritis and pulmonary, central nervous system, coronary or 
peripheral emboli 
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TABLE 2.  Duke criteria (2). 
Definite infective endocarditis. 
Pathological criteria: Microorganisms demonstrated by culture or histology in a vegetation, 
or in a vegetation that has embolized, or in an intracardiac abscess, or pathological 
lesions: vegetation or intracardiac abscess present, confirmed by histology showing active 
endocarditis 
Clinical criteria, using specific definitions (listed in Table 3): 
Two major criteria, or one major and three minor criteria, or five minor criteria 
Possible infective endocarditis. Findings consistent with infective endocarditis that fall 
short of ”definite”, but not rejected 
Rejected.  
Firm alternative diagnosis for manifestations of endocarditis, or resolution of 
manifestations of endocarditis with antibiotic therapy for four days or less, or no pathologic 
evidence of infective endocarditis at surgery or autopsy after antibiotic therapy for four 
days or less 
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TABLE 3. Definitions of terminology used in the Duke criteria (2). 
Major criteria 
Positive blood culture for infective endocarditis 
Typical microorganism for infective endocarditis from two separate blood cultures: 
(i) Streptococcus viridans 3, Streptococcus bovis, HACEK4 group, or 
(ii) community-acquired Staphylococcus aureus or enterococci, in the absence of a 
primary focus, or  
Persistently positive blood culture, defined as recovery of a microorganism consistent 
with infective endocarditis from: 
(i) blood cultures drawn more than 12 h apart, or 
(ii) all of three or a majority of four or more separate blood cultures, with first and 
last drawn at least one hour apart  
Evidence of endocardial involvement 
 Positive echocardiogram for infective endocarditis: 
(i) Oscillating intracardiac mass on valve or supporting structures, or in the path of 
regurgitant jets, or on implanted material, in the absence of an alternative anatomic 
explanation or 
(ii) abscess or 
(iii) new partial dehiscence of prosthetic valve, or  
New valvular regurgitation (increase or change in pre-existing murmur not sufficient) 
Minor criteria 
- Predisposition: predisposing heart condition or intravenous drug use 
- Fever: ≥38.0°C (100,4 °F) 
- Vascular phenomena: major arterial emboli, septic pulmonary infarcts, mycotic 
aneurysm, intracranial hemorrhage, conjunctival hemorrhage, Janeway 
lesions 
- Immunologic phenomena: glomerulonephritis, Osler’s nodes, Roth spots, 
rheumatoid factor 
- Microbiologic evidence: positive blood culture but not meeting the major 
criterion noted previously5 or serologic evidence of active infection with 
organism consistent with infective endocarditis 
- Echocardiogram: consistent with infective endocarditis but not meeting the 
major criterion noted previously 
3Including nutritional variant strains. 4HACEK: Haemophilus spp., Actinobacillus 
actinomycetemcomitans, Cardiobacterium hominis, Eikenella spp., and Kingella kingae. 5Excluding 
single positive culture for coagulase-negative staphylococci and organisms that do not cause 
endocarditis 
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3.2.3 Blood culture  
 
 Papers I, II and III 
According to the protocol, a standardized series of three blood cultures were drawn 
with three separate venous punctures with intervals of at least 20 minutes. In Göteborg, 
one aerobic and one anaerobic bottle (the biphasic model modified Castaneda system) 
were used at every blood culture when the study began in 1984. The bottles contained 
2.5 ml of blood each in the first 21 months of the study (altogether 5 ml). This 
procedure changed to an increased blood volume of 5 ml per bottle (altogether 10 ml) 
in 1986.  
 
The BACT / ALERT SYSTEM (Organon Teknika Corp, Durham, NC, US) was introduced 
for specimens from most Göteborg patients in the study in 1993. 20 ml of blood was 
divided into one aerobe and one anaerobe bottle at every blood culture. FAN (aerobic 
and anaerobic media composed of brain heart infusion broth and Ecosorb (contains 
absorbent charcoal and Fullers earth) media were introduced in 1995 instead of 
standard media. All blood cultures collected in Göteborg were incubated for 10 days. 
Blood samples from the Borås patients (1989-96) were cultured in the SIGNAL system 
of OXOID (Basingstoke, United Kingdom). In this system, only one bottle containing 
10 ml of blood was used on every blood culture occasion. The incubation time was 7 
days. 
 
Paper IV 
The local departments of microbiology, most often situated at the same hospital as the 
Infectious Diseases Departments, analyzed the blood cultures, which were sent to 
them. The automated blood culture systems most often used during the period 1995-
2004 were the BacT/Alert and BACTEC systems.  About 20 ml blood in every draw 
was divided into one aerobe and one anaerobe bottle at least twice but usually three 
times in every episode.  The blood was incubated for 7 to10 days before test results 
were confirmed as culture negative. 
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3.2.4 Serology  
 
Paper II  
Bartonella and C. burnetii 
One serum sample collected from each IE patient before therapy began was tested for 
antibodies to B. quintana, B. henselae, C. burnetii.  B. quintana, Oklahoma strain, and 
B. quintana, Marseille strain isolated from a French patient (ATCC 49882T). B. 
henselae, serotype Marseille B, and B. henselae, Houston-strain  were used as antigens. 
The bacteria taken between the fourth and seventh passages in a human endothelial cell 
line were harvested, pelleted and used as crude antigen in a MIF assay (85, 86). The 
current cut-off levels for diagnosis of Bartonella endocarditis has been estimated at ≥ 
800 IgG antibodies with a positive predictive value (PPV) of 0.955 in patients with IE 
(87). Patients with titers between 50 and 200 may have been in contact with cats and 
have a residual positive serology (86). Q-fever serology was performed with a MIF 
assay to identify antibodies to C. burnetii antigen [29] . The cut-off level for diagnosing 
chronic Q-fever was phase I IgG ≥ 800 with a PPV of 0.98. 
 
Paper III 
C. pneumoniae  
For analysis with a modified MIF (88), patients’ sera were diluted 1:16 (for IgM and 
IgA antibodies) and 1: 32 (for IgG antibodies) in phosphate buffered saline pH 7.4, 
and tested for IgG, IgA and IgM antibodies on 21- well antigen slides containing 
elementary body preparations of C. psittaci, C. pneumoniae and Chlamydia 
trachomatis in each well  (Lab Systems Oy, Finland), as previously described (88). 
Sera positive in screening tests for IgG were rediluted and tested in doubling 
dilutions. Sera positive in screening tests for IgA and/or IgM were mixed with 
Gullsorb (Gull Laboratories, US) at a dilution of 1:16 to remove all IgG and then 
titrated in doubling dilutions with PBS (89). The same investigator blinded to 
case/control status read all slides. Control sera routinely used in the laboratory were 
included in every test run, and test results were  accepted only when the control sera  
were within one titer step of the mean calculated earlier. The last dilution step to give 
a specific fluorescent pattern was reported as the reciprocal titer (88).  
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A C. pneumoniae titer of IgG antibodies ≥512 and a C. pneumoniae IgA ≥64 antibody 
titer were chosen as cut-offs for presumptive acute reinfection or persistent infection 
(89). 
   
3.2.5 Echocardiography 
 
Paper I 
The Göteborg patients were examined at the Department of Clinical Physiology, 
Sahlgrenska University Hospital and the Borås patients at the Department of 
Cardiology, Södra Älvsborgs Hospital. The investigators used exclusively the TTE 
method until the end of the 1980s when TEE was introduced.  This latter method was 
added increasingly to the diagnostic procedures during the study period until, by the 
program’s end, most patients underwent TEE.  
 
Paper IV 
Echocardiography was performed with TTE and/or TEE at the local hospital according 
to local and general recommendations from the Guidelines in Infective Endocarditis 
from The Swedish Society of Infectious Diseases (78).   
 
3.2.6 Statistics 
 
Values of quantitative variables were expressed as means, medians and range (in 
brackets []) in all papers. 
 
Paper I 
Confidence limits (95% level) were given in brackets [95% CI]. The Chi square test 
was used to test the difference between proportions. A significance level of 0.05, two-
tailed test was used. Yates correction was applied when applicable. 
 
Paper II 
No calculations performed. 
 
Paper III  
The probability of C. pneumoniae IgG ≥512 and C. pneumoniae IgA ≥64 in persons 
who are 70 years old was estimated by using a logistic regression analysis. Adjusted 
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odds ratios (aOR) were calculated taking age into account by using the multiple logistic 
regression. Confidence limits (95% level) were given in brackets [95% CI]. 
 
Paper IV 
 Odds ratios (OR) were calculated with 95% confidence limits [95% CI] or exact 
confidence limits when needed (StatCalc, EpiInfo-6). The differences in mortality in 
patients with or without aminoglycoside therapy were compared with an aOR (adjusted 
for age and gender) using the multiple logistic regression analysis (EpiINFO). A 
significance level of 0.05, two-tailed test was used. Yates correction and Fishers exact 
test were used when appropriate.  
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4 RESULTS AND DISCUSSION 
 
4.1 THE PROPORTION OF CNE IN SWEDISH IE PATIENTS, A 
DESCRIPTION AND AN ANALYSIS OF CLINICAL DATA IN CNE 
PATIENTS (PAPERS I AND IV) 
 
The proportions of CNE in episodes of IE in Sweden appear in Table 4. Paper I 
records 116, and Paper IV encompasses 304 such episodes. Studies from several 
countries world wide estimating the proportion of CNE in IE episodes are 
documented in Table 5, and Table 6 depicts patients’ demographic and clinical 
features as well as comparing blood culture-negative and -positive IE. The mortality 
rates in men and women are compared in Table 7. 
 
TABLE 4. The estimated proportions of CNE in different Swedish populations (Papers I and 
IV). 
PLACE TIME ALL IE EPISODES CNE EPISODES (%) 95% CI (%) 
Göteborg 1984-88 161 (Paper I) 34 (21) [15-28] 
Göteborg 1989-96* 256 (Paper I) 48 (19)  [14-24] 
Borås 1989-96 70 (Paper I) 19 (27)  [18-37] 
Sweden 1995-2004* 2509 (Paper IV) 304 (12) [9-15] 
IE (infective endocarditis), CNE (blood cultures negative for IE), CI (confidence interval), 
*Duke definite and possible episodes only. 
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TABLE 5. The proportion of CNE in IE patients in different study populations. 
 IE 
EPISODES 
(N=) 
PERCENTAGE 
CNE OF ALL  IE 
EPISODES 
YEAR 
(S) 
DIAGNOSTIC 
CRITERIA  
Göteborg, 
Sweden  
secondary and 
tertiary referral 
center (1) 
99 12 1984-
1988 
Von Reyn (modified 
with echocardio-
graphic findings) 
France (multi-
center) (5) 
620 10 1990-
1991 
Von Reyn (modified 
with echocardio-
graphic findings) 
France (multi- 
center) (11) 
390 5 1999 Duke definite  
 Beirut, Lebanon 
(9) 
91 23 1986-
2000 
Duke definite and 
possible 
Athens, Greece 
(7) 
101 18 1997-
2000 
Duke definite and 
possible 
Cape Town, 
South Africa 
(tertiary referral 
center) (8) 
60 55 1997-
2000 
Duke definite 
 Copenhagen, 
Denmark (tertiary 
referral center) 
(13) 
132 18 1998-
2000 
Duke definite and 
possible 
Marseille, France 
(secondary and 
tertiary referral 
center) (6) 
170 10 1994-
2000 
Duke definite 
Argentina (multi- 
center) (4) 
390 11 2001-
2002 
Duke definite  
Alger, Algeria 
(secondary and 
tertiary referral 
center) (10) 
110 56 2000- 
2003 
Duke definite and 
possible 
Turku, Finland, 
(tertiary referral 
center) (12) 
155 20 1995-
2004 
Duke definite and 
possible 
Göteborg, 
Sweden 
prospective  
(secondary and 
tertiary referral 
center) (90), 
Paper I 
256 19 1989-
1996 
Duke definite and 
possible 
Sweden (multi 
center), Paper IV  
2509 12 1995-
2004 
Duke definite and 
possible 
Sweden (multi-
center), Paper IV 
1952  4  1995-
2004 
Duke definite 
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TABLE 6. Patients’ demographic and clinical features: comparison of blood culture negative 
(CNE) and blood culture   positive endocarditis (CPE). 
 
PATIENTS 
CNE 
GÖTEBORG, 
BORÅS - PAPER I 
(N=116) 
CNE 
SWEDEN 
PAPER IV 
(N=304) 
CPE 
SWEDEN 
PAPER IV 
(N=2205) 
Females  50% 42% 35% 
Age in years, median  
[range] 
67 [19-85] 68 [17-89] 66 [14-100] 
Prosthetic valve 24% 19% 18% 
Previous endocarditis 13% 10% 10% 
Injection drug use 1% 3% 12% 
Aortic valve infection 42% 50% 38% 
Mitral valve infection 30% 29% 34% 
Aortic and mitral valve 
infection 
8% 7% 7% 
Tricuspid valve 
infection 
0% 5% 11% 
Duke criteria (Definite/ 
Possible/ 
Reject¹) 
20 (17%)/ 
80 (69%)/ 
16 (14%) 
83 (27%)/ 
221 (73%) 
1869 (85%)/ 
336 (15%) 
Echocardiography 98% 99% 99% 
TTE 91% 66% 69% 
TEE 33% 82% 78% 
Vascular phenomena 
(emboli) 
16% 21% 35% 
Mortality during 
treatment 
7% 5% 11% 
Registered possible 
relapses 
3% 2% (3/1522) 2% (23/11162) 
Deceased during 
follow up 
No data 6% (4/1522) 7% (39/11162) 
Antibiotic treatment 
and surgery 
(15%) 15% (46/297³) 21% (453/21524)  
¹Reject episodes not studied (paper IV). 2Follow-up visit. ³Data about antibiotic treatment 
missing for seven episodes. 4Data about antibiotic treatment missing for 53 episodes. 
 
In the Swedish IE registry study the mortality for patients with CNE and CPE was 5% 
vs. 11%, respectively, a disparity that reached statistical significance with an odds ratio 
of 0.38 [95% CI 0.21- 0.68].  
 
TABLE 7. Comparison of mortality in CNE and CPE in Sweden (1995-2004) (Paper IV). 
 CNE  CPE  ALL IE  
Mortality 5 % (n=304)) 11 % (n=2205) 10.3 % (n=2509) 
Mortality 
Women/Men 
9 % (n=127)/  
2 % (n=177) 
13 % (n=764)/ 
10 % (n=1441)  
12.1% (n=891)/ 
9.4% (n=1618) 
Female vs. 
male episodes. 
Odds ratio(OR) 
5.5 [95% CI 1.40-31.2]  1.26 [95% CI 0.95-1.67] 1.33 [95% CI 1.02-1.74] 
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We studied the influence of antibiotic pre-treatment on blood cultures, as described in 
Paper I (Figure 2). In 45% [(95%CI) 36-55] of the episodes antibiotic therapy might 
have influenced the results from blood cultures. In 16% of all episodes, such therapy 
stopped less than 60 days [median 7 [1-41] before blood was cultured.  
 
FIGURE 2. Antibiotic pre-treatment for CNE episodes. 
 
CNE was found in 12 to 27 % of all Swedish IE episodes (Table 4). The lowest of these 
percentages is an estimate from data in the Swedish registry  (n=2509 episodes) and the 
highest percentage is from the smallest data set collected retrospectively in a second-
line hospital (Borås) (n=70 episodes). The estimates calculated for CNE were 19 to 
21% in the prospectively collected IE episodes in the Göteborg study. Although the 
large size of the Swedish registry study increases the precision of estimated values, the 
validity of data may be influenced by selection bias (91). A disease like CNE may be 
difficult to diagnose and therefore not registered. The proportion of Duke “definite” 
CNE in the Swedish registry study was 27% compared to 17% in the Göteborg IE 
study, a difference that points out that the CNE episodes which were reported could 
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have been more obvious IE cases. The absence of positive blood cultures may be one 
reason not to perform echocardiography, which in turn may cause some CNE episodes 
to remain undetected. Although IE is not a self-limiting disease, it may be cured by 
short-term treatment with intravenous antibiotics. In fact, the Duke criteria consider this 
possibility when differentiating between the “possible” and “reject” groups.  
 
The high proportion 27%, of CNE found in the Borås study may be a chance 
estimate, since the confidence limits were wide. Undoubtedly, the estimate that about 
20% of patients with IE could be classified as having CNE among the prospectively 
analyzed Göteborg group is the most trust worthy calculation in this comparison. Our 
results coincide with other modern studies of CNE in Europe, measured at 5 to 20% 
of IE episodes (6, 9, 11-13, 90), (Table 5). The lowest figures emerged in IE patients 
who belonged to the Duke “definite” group (11). 
 
Patients with CNE studied here had a mortality rate of 5 to 7% (Table 6), which is 
lower than the 10.3% for patients with IE in Sweden during 1995-2004. Moreover, 
the mortality rate for individuals with IE in Sweden is low compared with studies of 
IE recently published in other countries (14 to 26%) (4, 11, 92). The centralized 
treatment of patients with IE at infectious diseases departments and the low 
prevalence of methicillin-resistant S. aureus (93) during the period studied  have 
contributed to this low death rate.  
 
Mortality was lower for those with CNEs than for the CPE group (5% vs. 11%) in the 
Swedish study (Paper IV, Table 7). The relatively low mortality and low prevalence 
of acute valvular surgery in these patients with CNE may indicate that a milder 
variant of CNE may prevail in Sweden. Additionally, preparedness for early 
parenteral antibiotic treatment may have affected this positive outcome. Also of 
importance is that no episodes of Q-fever or infections with Bartonella were reported 
(94); if present; such infections could have  worsened the outcome of IE. 
 
A fatal outcome was significantly more common in females with CNE, in females 
with IE (culture positive and -negative episodes) but not in women with positive 
blood cultures (Table 7). This increased risk indicates that treatment and diagnostic 
procedures for women with IE need improvement.  
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Data from CNEs are in relatively good agreement with episodes of blood culture-
positive patients (Table 6). The absence of positive blood cultures explains the low 
proportion of Duke “definite” episodes in those groups compared to the CNE groups 
(5, 52, 90, 95), because blood culture findings are one of the cornerstones of the Duke 
criteria (2). Few intravenous drug users (IVDU) were counted in the CNE group 
correlating with the low prevalence of tricuspid IE, which is a common manifestation 
of IE in IVDU. 
 
We used the term possible relapse as a new event of IE during the six months after 
completed IE therapy.  If confirmational testing by molecular analysis is not 
performed, the terms relapse and reinfection are inadequate (96). Obviously, the term 
reinfection is difficult to use in patients with CNE.  
 
Antibiotic treatment preceded blood culture in 45% of all CNEs (Paper I). Since, as 
stated earlier, the influence of antibiotic pretreatment is very important (15),  all 
episodes in patients with ongoing or completed antibiotic treatment preceding testing 
have been analyzed together in relation to blood culture. The median time from 
withdrawal of antibiotic treatment to blood culture was seven days, and outcomes of   
patients in that post-treatment group accounted for 16% of the episodes. The length of 
antibiotic pretreatment has been proposed to have a great influence on the inhibition of 
bacterial growth in subsequent blood cultures (97). The median duration of antibiotic 
therapy was 10 days in our study. Initially, the volume of blood used for cultures was 
rather small altogether 5 ml per puncture. In 1993, the cultured blood volume changed 
from 10 to 20 ml (90) and the amount presently used is 20 ml per culture. In spite of 
this increased volume, however, no significant change followed in the proportion of 
CNE among IE patients in Göteborg during the period 1989-96 (86). We did not assess 
the issue in blood culturing of the time from venepuncture to start of incubation, but the 
length of that interval could have had an impact on the outcomes of testing for bacterial 
content. For example, the growth of viridans streptococci in blood cultures may be 
inhibited by antibiotic pretreatment (1, 15, 29, 98). 
 
Finally, to improve diagnostic accuracy in patients with suspected IE, it is important 
that excised valves in IE patients are subjected to histological examination, culturing 
(32), microbiology Gram staining (29) and, in selected cases, PCR investigation (32).  
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4.2 A COMPARISON OF THE DUKE CRITERIA AND THE MODIFIED 
BETH ISRAEL CRITERIA (PAPER I) 
 
One hundred and sixteen CNEs were evaluated with the Duke criteria and the Beth 
Israel criteria. Twenty episodes were assigned to the Duke “definite” and 13 to the Beth 
Israel ”definite” categories (Table 8). Sixteen episodes were classified as Duke 
“rejects” compared to 61 episodes to the Beth Israel “reject” group. 
 
TABLE 8. Duke and Beth Israel criteria for IE compared. 
BETH ISRAEL DUKE 
 DEFINITE POSSIBLE REJECT TOTAL 
Definite 5 8 0 13 
Probable 7 8 0 15 
Possible 6 21 0 27 
Reject 2 43 16 61 
Total 20 80 16 116 
 
 As shown in Table 8 and described in Paper I (90) (1, 2), 20 episodes fulfilled the 
criteria for definite IE in Duke’s classification. Valvular culture and histological 
investigation were not performed for four of the 17 patients who underwent surgery. 
The Duke criteria classified episodes as possible IE, even though resected valves from 
that patients showed macroscopic signs of IE. Consequently, the Duke criteria for 
“definite” may have been insensitive for assessing this group. 
 
 The largest classification of this population was Duke “possible” IE, accounting for 80 
of the 116 CNEs. This group was heterogeneous, including patients with a high 
likelihood of IE but also patients with very low likelihood despite four or more days of 
treatment for IE, because no other diagnosis seemed applicable. Thirty-nine episodes in 
the Duke “possible” group fulfilled the requirement for one major criterion and two 
minor criteria. In diagnosing CNEs, the major endocardial criterion is very important in 
the absence of positive blood cultures. Only 38 of the CNEs in Paper I were 
investigated with TEE. This sensitive method might have detected more episodes with 
the major endocardial criterion. Additionally, no investigation of immunological 
phenomena such as rheumatoid factor was done according to the study protocol, 
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although positivity for rheumatoid factor would certainly have classified more episodes 
as definite IE (99).  
 
In 27 of the 80 possible CNEs, only two minor criteria were present (i.e., fever >38.0°C 
and a predisposing heart condition). Valvular prosthesis, an earlier episode of IE, 
atherosclerotic valves or congenital heart disorder and fever were noted.  Clearly, 
classifying patients with a valvular prosthesis and fever as Duke “possible” IE is too 
simplistic. We agree with proposed modifications of the Duke criteria to increase the 
specificity of the “possible” class and concur that at least three minor criteria or one 
major and one minor criterion are necessary to classify an episode as possible IE (77). 
TEE should be used to enhance the ruling of “possible” and separate that group from 
the “reject” group via the Duke criteria (100). If the Duke criteria become more 
specific, they could be used as tools in bedside decision-making to determine whether 
or not antibiotic therapy should be administered.  
 
 We found that the Duke criteria were more sensitive than the modified Beth Israel 
criteria in identifying “definite” episodes of IE (20 vs. 13). However, it is more useful 
comparing the modified Beth Israel criteria “definite” and “probable” groups (the latter 
group included patients who neither underwent surgery nor died) with the Duke 
definite group evincing an increased sensitivity for 28 vs. 20 episodes. 
 
The modified Beth Israel criteria distinguished 61 episodes as rejects, indicating a 
better specificity compared to 16 rejected episodes with the Duke criteria. This better 
discriminating ability results from the fact that the Beth Israel criteria disregard the time 
of IE treatment (more or less than four days) and do not require a firm alternative 
diagnosis to reject IE, which sometimes is impossible in a clinical situation.  
 
 
4.3 ANTIBIOTIC THERAPY IN CNE (PAPER IV) 
 
We studied the influence of aminoglycoside treatment for the outcome of CNE (Table 
9) and found that CNE patients who received aminoglycoside treatment had a 
significantly decreased risk of mortality, aOR 0.26. Alternative antibiotic therapies used 
in the treatment of CNE and CPE are listed in Table 10. 
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TABLE 9. Effect of aminoglycoside on mortality from CNE. 
 DEATHS 
AMINOGLYCOSIDE 
THERAPY N= (%) 
DEATHS  
NO AMINOGLYCOSIDE 
THERAPY N= (%) 
aOR [95%CI]¹ p=¹ 
CNE 
N=297 
8/249 (3) 6/48 (13) 0.23 [0.08-0.85] 0.03 
 
¹adjusted for age and gender 
 
TABLE 10. Antibiotic therapy in 297 CNE episodes and 2152 CPE IE episodes. 
 ANTI-
BIOTIC 
THERAPY 
 
β-
LACTAM 
 
AMINO-
GLYCO-
SIDE 
 
AMINO-
GLYCO-
SIDE 
AND β- 
LACTAM 
 
VANCO-
MYCIN 
 
RIFAM-
PICIN 
ALL CNE 
n=(%),  
treatment 
days 
median 
[range] 
 
297¹ (100) 
 
 
28 [1-101] 
 
 
261 (88) 
 
 
28 [2-77] 
 
249 (84) 
 
 
14 [2-63] 
 
232 (78) 
 
 
14 [1-49] 
 
81 (27) 
 
 
21 [2-83] 
 
12 (4) 
 
 
27 [6-56] 
NVE 
n=(%),  
treatment 
days 
median 
[range] 
 
240 (100) 
 
 
28 [1-101] 
 
216 (90) 
 
 
28 [2-77] 
 
201 (84) 
 
 
14 [2-56] 
 
192 (80) 
 
 
14 [1-40] 
 
57 (24) 
 
 
15 [2-83] 
 
8 (3) 
 
 
21 [6-43] 
PVE 
n=(%),  
treatment 
days 
median 
[range] 
 
57 (100) 
 
 
28 [1-89] 
 
45 (79) 
 
 
25 [2-80] 
 
48 (84) 
 
 
14 [3-63] 
 
40 (70) 
 
 
14 [1-27] 
 
24 (42) 
 
 
30 [2-56] 
 
4 (7) 
 
 
42 [21-56] 
ALL CPE 
n=(%),  
treatment 
days 
median 
[range] 
 
2152² (100) 
 
 
30 [1-133] 
 
 
2005 (93) 
 
 
28 [1-133] 
 
1831 (85) 
 
 
14 [1-61] 
 
1758 (81) 
 
 
14 [1-61] 
 
494 (23) 
 
 
14 [1-98] 
 
190 (9) 
 
 
18 [1-90] 
¹No data in seven other episodes, ²No data about antibiotic treatment in 53 other episodes 
 
The higher rate of mortality in patients without aminoglycoside therapy (p=0.03) 
described in Paper IV and confirmed in Table 9 supports the inclusion of 
aminoglycoside in the treatment regimen for CNE, as suggested in recently published 
guidelines from the US (79) and Europe (80). This finding is particularly important, 
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because the impact of aminoglycoside treatment for IE has attracted a great deal of 
attention in recent years (101, 102).  
 
Seventy-eight percent of all CNE patients studied here received combination therapy 
with an aminoglycoside and a beta-lactam antibiotic, but fewer patients had this 
combination in the PVE group (70%) Table 10. Vancomycin was the predominant 
treatment for CNE PVE compared to that for NVE (42% vs. 24%, respectively). Only 
twelve patients received treatment with rifampicin, four (7%) with CNE PVE and eight 
(3%) with NVE; therefore, the impact of rifampicin treatment for CNE warrants further 
study. Overall, we documented good agreement with respect to antibiotic treatment 
received by patients with culture negative and -positive IE.  
 
 
4.4  SEROLOGICAL SIGNS OF BARTONELLA, C. BURNETII AND 
C.PNEUMONIAE (PAPERS II, III) 
Q-fever and Bartonella 
Three hundred and thirty-four blood samples were analyzed with Bartonella and  
C. burnetii serology (Paper II). In no case was the cut-off antibody level for Bartonella 
serology IgG ≥800 reached. C. burnetii serology consistent with Q-fever endocarditis 
with phase I antigen IgG 1000 was detected in one patient.  
 
C. pneumoniae 
No significant differences appeared when C.  pneumoniae antibodies were compared in 
patients with blood culture and -positive episodes of IE   (Table 11).  
 
TABLE 11. C. pneumoniae antibodies in patients with blood culture negative and -positive 
episodes of IE. 
MEN WOMEN  
CNE% CPE % 
 aOR¹ 
[95 % CI] 
CNE% CPE % 
aOR¹ 
[95 % CI] 
C. pneumoniae 
IgG ≥512 
42 30 1.69 
[0.84-3.33] 
40 29 1.69 
[0.83-3.45]
C. pneumoniae 
IgA ≥64 
53 41 1.61 
[0.79-3.23] 
40 29 1.61 
[0.79-3.23]
¹ age adjusted 
 30 
The screening of sera from 334 episodes of IE did not disclose any undiagnosed cases 
of Q-fever or Bartonella infection. During the period studied in Göteborg (103, 104),  
body lice were seldom found, and none of the investigated patients was homeless. The 
only patient with an increased level of phase I antibodies to C. burnetii had a previously 
diagnosed and treated Q-fever endocarditis (105, 106) probably acquired in Crete, 
Greece. Although this was the only patient with Q-fever endocarditis found here, we 
suggest that CNE patients should be screened for Q-fever. Many travelers go to 
countries where this infection is endemic, and the treatment for Q-fever differs from 
that recommended for CNE. 
 
 Despite the published case reports of C. pneumoniae IE (56, 57), considerable doubt 
remains that C. pneumoniae is the causes. Reinvestigation of patients diagnosed with 
C. pneumoniae IE a showed serologic cross reactions between Bartonella and C. 
pneumoniae, and the former was deemed to be the etiologic agent (107). Furthermore, 
no significant differences were seen in the proportions of patients with increased 
levels of C. pneumoniae antibodies when comparing CNE and CPE episodes (Paper 
III). Nearly all patients were screened for Bartonella by serological assays without 
finding any with IE. Consequently, our results do not support the hypothesis of C. 
pneumoniae as a cause of CNE. 
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4.5  C. PNEUMONIAE ANTIBODIES IN IE AND POPULATION CONTROLS 
(PAPER III) 
 
Since increased amounts of C. pneumoniae antibodies are frequently found in IE 
patients, we compared the titers in their blood with those from the control populations 
(Table 12). 
 
TABLE 12. C.  pneumoniae antibodies in IE patients  and population controls. 
MEN WOMEN 
 
IE%¹ CONTROLS%
aOR 
[95 % CI] IE%¹ CONTROLS% 
aOR 
[95 % CI] 
C.pneumoniae 
IgG ≥512 
33 26 
1.37 
[0.83-2.27]
32 17 
2.21 
[1.32-3.70]
C.pneumoniae 
IgA ≥64 
45 31 
1.80 
[1.12-2.91]
32 10 
3.98 
[2.26-7.01]
¹ age adjusted 
 
 Our results documented significantly higher C. pneumoniae IgG and IgA antibody 
levels in the females with IE than in female controls. C. pneumoniae IgA antibody 
levels were also increased in males with IE compared to their controls.  However, these 
results should be judged with caution. Although adjusted for age and gender, the results 
were not adjusted with respect to smoking, hypertension or obesity, which are proposed 
confounding factors in studies of aortic valve sclerosis (108, 109). 
 
 Detection of IgG antibodies in serum can be expected years after the initial infection, 
and a serum IgG of ≥ 512 may indicate either a chronic infection and/or earlier 
infection with C.pneumoniae. Distinguishing between these two options might have 
been possible by analyzing sequential sera samples. However, it is uncertain whether 
the results of antibody tests in our patients mirror true Chlamydia infections in heart 
valves, since we did not have the opportunity to study tissues from our patients. The 
association between C. pneumoniae antibodies and valve sclerosis is not proven (61). 
Although C. pneumoniae has been detected in calcified aortic valves with 
immunohistochemistry and/or PCR (59, 60, 62, 110), results from other such studies 
disagreed (61, 63, 65). Moreover, the correlation of raised C. pneumoniae IgG and IgA 
antibody content in sera and of C. pneumoniae infection in heart valves is not fully 
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investigated (61, 62, 111). C. pneumoniae has been found in atherosclerotic lesions, so 
this bacterium could be either an innocent bystander or a co-pathogen in the 
pathogenesis of endocarditis. 
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5 CONCLUSIONS 
 
 
1. The proportions of CNE in IE episodes were estimated at 12% in the Swedish 
IE registry study and 19 to 27 % at Göteborg and Borås clinics. The mortality 
during treatment was 10.3% in all registered IE episodes in Sweden and 5 to 7% 
in the CNEs. There was a significant higher death rate in women with CNE than 
in men with CNE. Antibiotic treatment preceded blood culture in 45% of all 
CNEs. 
 
2. For establishing IE diagnosis, the Duke definite criteria were more sensitive 
but probably less specific than the Beth Israel criteria. 
 
3. Aminoglycoside treatment was associated with a significantly lower mortality 
in CNE patients. 
 
4. Bartonella and Q-fever-related IE were rare in Sweden, and this study does not 
support the hypothesis that C. pneumoniae causes CNE. 
 
5. We found a higher prevalence of C. pneumoniae antibodies in women with IE 
compared to female population controls. 
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6  ASPECTS FOR THE FUTURE 
 
The study of CNE needs access to new tools for accurate diagnoses of bacterial 
infections from patients’ blood samples. Although the PCR method for detecting 
microorganisms in the blood have been considered promising for the past 15 years, no 
real breakthrough has occurred in the study of bacteria and fungi. Serological methods 
may be difficult to interpret and are often not specific. Antibiotic pretreatment before 
testing blood cultures is still common. For that reason, the practice of culturing and 
analyzing blood from outpatients with fever despite a rather small suspicion of IE 
should be further encouraged. Patients given parenteral antibiotic therapy should 
always undergo blood culture analysis before antibiotic administration. An important 
adjunct to these conclusions is the continued development of new blood culture media 
with improved inhibitors to the effect of antibiotics. 
 
We still rely on analysis of heart valve tissue for a definite diagnosis of IE. Therefore, 
when a patient with CNE undergoes valvular surgery or dies after a CNE, it is of 
utmost importance that the resected valves are sent for histopathology, microbiological 
Gram staining, valvular culture and, in selected cases, PCR investigation. Although 
some series of resected valves from IE patients have been handled in this way, the 
incidence is small in view of the far larger number of patients involved and further 
studies are wanted. 
 
Our data shows that, to some extent, clinicians are overdiagnosing CNE. If all patients 
with fever not clearly related to a specific disease are screened with echocardiography, 
considering its current high sensitivity and specificity, we believe that many patients 
with vegetations or other suspicious valve alterations will be suspected as having IE. 
However, echocardiography is not a screening method for IE in patients with fever of 
short duration and no clinical signs of heart disease. 
 
Clearly, the role of aminoglycosides in IE therapy needs to be studied further, because 
of its potential for harm. 
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The study indicates higher mortality in women with IE than men. Therefore, future 
studies should be addressed studying the influence of gender in the diagnosis, treatment 
and outcome of IE.  
 
Although the improvements in diagnostic procedures facilitate the exclusion of the 
diagnosis of CNE in suspected IE patients, CNE occurs in about one fifth of all cases 
of IE. Antibiotic treatment preceding blood culture diminishes the value of a negative 
test result.  Fastidious bacteria are mainly diagnosed with antibody determinations, 
which may be difficult to interpret and take a long time to get. Consequently, 
clinicians still need better methods for discriminating CNE from other diseases.  
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Abstract: Culture-negative infective endocarditis (CNE) is a di-
agnostic problem in spite of improved echocardiographic and
blood culturing techniques. We conducted the present study to es-
timate the proportion of CNE in patients with infective endocardi-
tis, to investigate data regarding risk factors, and to evaluate the
Duke and the modified Beth Israel criteria in patients with CNE.
We evaluated 820 consecutive suspected episodes of infective en-
docarditis in adults at the Departments of Infectious Diseases in
Göteborg and Borås, Sweden (1984–1996). All patients were di-
agnosed and treated according to a protocol; 487 episodes were
identified as infective endocarditis. Episodes with absence of bac-
terial growth at blood culture were defined as CNE and were clas-
sified with the Duke and the modified Beth Israel criteria.
We identified 116 CNE episodes (median age, 67 yr). Mortality
was 7%, and in 15%, cardiac surgery was performed. The Duke
criteria classified 20 definite, 80 possible, and 16 reject episodes.
The modified Beth Israel criteria distinguished 13 definite, 15
probable, 27 possible, and 61 reject episodes. The proportion of
CNE among patients with infective endocarditis varied from 19%
to 27% at the 2 departments. Antibiotic treatment preceded
blood culture in 45% of the CNE episodes.
About 20% in a Scandinavian population of infective endocardi-
tis patients have CNE. Antibiotic pretreatment explains less than
50% of all CNE episodes. The Duke criteria are more sensitive
but less specific than the modified Beth Israel criteria in classify-
ing patients with CNE.
(Medicine 2003;82: 263–73)
INTRODUCTION
Positive blood cultures are keystones in diagnosing in-fective endocarditis. However, blood culture-negative
endocarditis (CNE) is detected in both population-based
epidemiologic studies and hospital studies of infective en-
docarditis. The proportion of CNE among infective endo-
carditis patients in different studies has been estimated at
1%-55% (6, 18, 20, 30, 38, 40). The marked difference be-
tween studies has been explained by inadequate blood cul-
turing techniques, antibiotics preceding blood culture, and
different criteria for diagnosis.
To our knowledge, only 1 clinical epidemiologic
study (18) has concentrated on patients with CNE during
the last decade, a nationwide survey of infective endo-
carditis patients in France describing 88 patients with
CNE. Previous antibiotic treatment was found in 48% of all
cases, mortality was 15%, and a causative agent was found
in 17% of all episodes. Fifty-one percent of the episodes
were defined as definite according to the Duke criteria (11).
Infective endocarditis has been prospectively studied
at the Department of Infectious Diseases, Göteborg Uni-
versity, Sweden, since 1984. The proportion of CNE was
estimated earlier (1984–1988) to be from 12% to 21% (20,
27), depending on which inclusion criteria were used. An-
tibiotic treatment preceded blood culture in 85% of the
CNE episodes, compared with 35% of the episodes in the
control group of blood culture-positive episodes. The
study was expanded to include the Department of Infec-
tious Diseases, Borås, Sweden, since 1989.
The Duke criteria (11) for classifying patients with in-
fective endocarditis have been established during the last
few years and have nearly replaced the Beth Israel criteria
(von Reyn criteria) (39), although the latter have been
modified to include findings at echocardiography (20, 27).
These classification systems have not been compared in
consecutively collected CNE episodes, to our knowledge.
We conducted the present study with the following
objectives: 1) to estimate the proportion of CNE in a group
of patients with infective endocarditis recruited in a sec-
ondary and a tertiary hospital in Sweden; 2) to describe and
analyze data from patients with CNE regarding suspected
risk factors and demographic data; and 3) to evaluate the
Duke and modified Beth Israel criteria in CNE patients.
PATIENTS AND METHODS
Setting
The study took place at the Departments of Infectious Dis-
eases at Sahlgrenska University Hospital, Göteborg, and Borås
Hospital, Borås, Sweden. The former is a university clinic and a
tertiary referral center and serves an urban population of about
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600,000 inhabitants. The latter is a second-level referral hospital
that serves a mixed urban and rural population of about 250,000
inhabitants.
Patients
The patients were prospectively recruited at the Göteborg
clinic between 1984 and 1996 and at the Borås clinic from 1989
through 1996. The patients were transferred from other depart-
ments as cases of suspected infective endocarditis or fever of un-
known origin; were referred by their general practitioner; or at-
tended the outpatient clinics. All patients were adults (18 yr).
We prospectively studied 233 consecutive episodes (217
patients) at the Göteborg clinic between 1984 and 1988. Of these
episodes, 161 (149 patients; 81 male, 80 female episodes) were
diagnosed as apparent infective endocarditis (20). Suspected in-
fective endocarditis was identified in 517 episodes (460 patients;
267 male and 250 female episodes) in Göteborg between 1989
and 1996: 145 episodes (89 male, 56 female episodes) were clas-
sified according to the Duke criteria (11) as definite, 111 (59 male,
52 female episodes) as possible, and 261 (119 male, 142 female
episodes) as rejects. Antibiotic combination therapy was initiated
in 363 of the 517 episodes. Records from 237 episodes, in patients
discharged with the diagnosis of infective endocarditis (Interna-
tional Statistical Classification of Diseases, ninth revision [ICD-
9]) at the Göteborg clinic from 1989 through 1996, were also eval-
uated to find CNE patients not registered in the prospective
study. In Borås, 70 episodes in 39 men and 31 women with an in-
fective endocarditis diagnosis (ICD-9) were found.
Study design
The study was a nonrandomized descriptive study of con-
secutive patients with CNE treated as infective endocarditis
according to a study protocol with uniform antibiotic treatment reg-
imens, clinical evaluation procedures, and collection of specimens.
Echocardiography was regularly done in the first week and, if in-
dicated, repeated at the fourth week of treatment. Transesophageal
echocardiography, available since 1991, was used when applicable.
The location of infective endocarditis was determined by surgery,
autopsy, or echocardiography. Patients who attended the Göteborg
clinic were regularly examined by a dentist but those in Borås, only
sporadically. Demographic data and data concerning suspected
risk factors and other preceding events were extracted from records
and registered in a standardized questionnaire.
All CNE episodes were evaluated with modified Beth Is-
rael criteria (20, 28) further modified to define only patients with
the absence of bacterial growth at blood culture as culture nega-
tive (Table 1). The episodes were also categorized according to
the Duke criteria (11) (Tables 2 and 3). Only lesions verified by
pathologic and anatomic diagnosis (PAD) or culture were ac-
cepted as definite by the Duke pathologic criteria.
Definitions
Patients with absence of bacterial growth in blood culture
and apparent infective endocarditis (1984–1988, Göteborg) were
defined as having CNE.
Patients with absence of bacterial growth in blood culture
and classified as definite or possible according to the Duke crite-
ria (1989–1996, Göteborg) were defined as having CNE.
Patients with absence of bacterial growth in blood culture
and discharged with an infective endocarditis diagnosis (ICD-9)
and not registered in the prospective studies were defined as hav-
ing CNE.
An episode was defined as an admission to hospital for
treatment of infective endocarditis, irrespective of the time inter-
val since any previous episode.
The first day of an episode was the first day of intravenous
antibiotic combination treatment.
Heart failure was defined as an increased demand for di-
uretics.
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TABLE 1. Modiﬁed Beth Israel criteria*, further modiﬁed so only patients with absence of bacterial growth at blood culture
were accepted as culture negative
1. Definite infective endocarditis
Episodes in patients for whom the diagnosis was verified at surgery or autopsy by culture, microscopy.
2. Probable infective endocarditis
Culture-positive endocarditis is characterized by at least 2/3 positive blood cultures and 1 of the following: new cardiac murmur, 
predisposing heart disease† with vascular phenomena‡, and/or sonographic evidence of vegetation.
Culture-negative endocarditis is characterized by negative blood cultures and all 3 of the following: fever, new cardiac murmur, 
and vascular phenomena.‡
3. Possible infective endocarditis
Culture-positive endocarditis is characterized by at least 2/3 positive blood cultures and 1 of the following: predisposing heart 
disease† and/or vascular phenomena.‡
Culture-negative endocarditis is characterized by negative blood cultures and all 3 of the following: fever, predisposing heart 
disease†, and vascular phenomena‡, alternatively sonographic evidence of vegetation.
Rejected
A. Endocarditis unlikely, alternative diagnosis generally apparent.
B. Endocarditis likely, empirical antibiotic therapy warranted.
C. Culture-negative endocarditis diagnosed clinically, but excluded by postmortem.
*References 20, 28.
†Valvular or congenital heart disease or valvular prosthesis.
‡Petechiae; splinter hemorrhage; conjunctival hemorrhages; Roth spots; Osler nodes; Janeway lesions; aseptic meningitis; glomerulonephritis; and
pulmonary, central nervous system, coronary, or peripheral emboli.
Treatment mortality was defined as all deaths during treat-
ment and up to 1 month posttreatment.
Blood culture and serology
According to the protocol, a standardized series of 3 blood
cultures was drawn with 3 separate venous punctures with inter-
vals of at least 20 minutes. In Göteborg, 1 aerobic and 1 anaero-
bic bottle (the biphasic model modified Castaneda system) were
used at every blood culture. The bottles contained 2.5 mL of
blood each in the first 21 months of the study (altogether 5 mL).
This procedure was changed to an increased blood volume of 5
mL per bottle (altogether 10 mL). The BACT/ALERT System
(Organon Teknika Corp., Durham, NC) was introduced for spec-
imens from most Göteborg patients in the study in 1993. At every
blood culture, 20 mL of blood was divided into 1 aerobe and 1
anaerobe bottle. FAN—aerobic and anaerobic media composed
of brain heart infusion broth and Ecosorb (contains absorbent
charcoal and Fullers earth)—media were introduced in 1995 in-
stead of standard media. All blood cultures collected in Göteborg
were incubated for 10 days.
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TABLE 2. Duke criteria*
Definite infective endocarditis
Pathologic criteria: microorganisms demonstrated by culture or histology in a vegetation, or in a vegetation that has embolized, or 
in an intracardiac abscess, or pathologic lesions: vegetation or intracardiac abscess present, confirmed by histology showing ac-
tive endocarditis.
Clinical criteria, using specific definitions listed (see Table 3): 2 major criteria, or 1 major and 3 minor criteria, or 5 minor criteria
Possible infective endocarditis
Findings consistent with infective endocarditis that fall short of “definite” but not rejected.
Rejected
Firm alternate diagnosis for manifestations of endocarditis, or resolution of manifestations of endocarditis with antibiotic therapy 
for 4 days or less, or no pathologic evidence of infective endocarditis at surgery or autopsy after antibiotic therapy for 4 or fewer
days.
*Reference 11.
TABLE 3. Deﬁnitions of terminology used in the Duke criteria*
Major criteria
A. Positive blood culture for infective endocarditis
1. Typical microorganism for infective endocarditis from 2 separate blood cultures:
a. viridans streptococci†, Streptococcus bovis, HACEK‡ group, or
b. Community-acquired Staphylococcus aureus or enterococci, in the absence of a primary focus, or
2. Persistently positive blood culture, defined as recovery of a microorganism consistent with infective endocarditis from:
a. Blood cultures drawn more than 12 h apart, or
b. All of 3 or a majority of 4 or more separate blood cultures, with first and last drawn at least 1 h apart
B. Evidence of endocardial involvement
1. Positive echocardiogram for infective endocarditis:
a. Oscillating intracardiac mass, on valve or supporting structures, or in the path of regurgitant jets, or on implanted material, 
in the absence of an alternative anatomic explanation, or
b. Abscess, or
c. New partial dehiscence of prosthetic valve, or
C. New valvular regurgitation (increase or change in pre-existing murmur not sufficient)
Minor criteria
A. Predisposition: predisposing heart condition or intravenous drug use
B. Fever  38.0 C (100 F)
C. Vascular phenomena: major arterial emboli, septic pulmonary infarcts, mycotic aneurysm, intracranial hemorrhage, conjuncti-
val hemorrhage, Janeway lesions
D. Immunologic phenomena: glomerulonephritis, Osler nodes, Roth spots, rheumatoid factor
E. Microbiologic evidence: positive blood culture but not meeting the major criterion noted previously§ or serologic evidence of
active infection with organism consistent with infective endocarditis
F. Echocardiogram: consistent with infective endocarditis but not meeting the major criterion noted previously
*Reference 11.
†Including nutritional variant strains.
‡HACEK: Haemophilus spp, Actinobacillus actinomycetemcomitans, Cardiobacterium hominis, Eikenella spp, and Kingella kingae.
§Excluding single positive culture for coagulase-negative staphylococci and organisms that do not cause endocarditis.
Blood from the Borås patients was cultured in the SIGNAL
system of OXOID (Basingstoke, UK). In this system, only 1 bot-
tle containing 10 mL of blood was used on every blood culture
occasion. The incubation time was 7 days. Coxiella burnetii serol-
ogy was performed in some suspected cases, but not regularly.
Statistical methods
Values of quantitative variables were expressed as means,
medians, and ranges. Confidence limits (95% CI) were given. The
chi-square test was used to test the difference between propor-
tions. A significance level of 0.05, 2-tailed test, was used. Yates
correction was used when applicable.
RESULTS
Patients
During the study period there were 116 episodes of
CNE in 115 patients (mean age, 63 yr; median age, 67 yr;
range, 19–85 yr). Nineteen episodes were identified at the
Borås clinic and 97 episodes (95 patients) at the Göteborg
clinic. Three patients were referrals to the Göteborg clinic
from other parts of western Sweden. The series consisted
of 58 episodes in men (mean age, 63 yr; median age, 64 yr;
range, 38–83 yr) and 58 episodes in women (mean age, 63
yr; median age, 70 yr; range, 19–85 yr). The actual pro-
portions of CNE in the prospectively studied populations
with infective endocarditis are presented in Table 4. Fif-
teen episodes identified retrospectively from records in
Göteborg from 1984 through 1996 were not included in
this calculation. The male/female ratio was 1.0 in the CNE
group (Duke reject group excluded).
Classification
The 116 episodes of CNE were divided into 20 defi-
nite, 80 possible, and 16 reject according to the Duke cri-
teria (11) and were also evaluated with the modified Beth
Israel criteria (20, 28) (Table 5). The alternative diagnoses
in the Duke reject episodes are shown in Table 6.
The proportion of CNE was estimated to be 6.4%
(16/251) (95% CI 3.8–9.9) in the Duke definite group and
40% (65/163) (95% CI 33–47) in the Duke possible group
(1984–1996, Göteborg prospective episodes). The distri-
bution of major and minor criteria in the Duke possible
group is presented in Figure 1. All consecutive prospective
episodes of suspected infective endocarditis in Göteborg,
1989–1996, were subdivided into an annual incidence and
sorted with the Duke criteria (Figure 2).
Presentation
Data concerning symptom duration, doctor’s delay,
and time to treatment are presented in Table 7. The me-
dian highest recorded temperature before infective endo-
carditis treatment was 39 C (range, 36.8-40.3 C).
Predisposing factors and risk factors
Data concerning suspected risk factors are presented
in Table 8. Thirty percent of the episodes occurred after
previous open heart surgery. The median time between
surgery and the start of infective endocarditis symptoms
was 26 months (mean, 62 mo; range, 0–385 mo).
Twenty-four percent of the episodes occurred in
prosthetic valve carriers. The median time from surgery to
first symptom of infective endocarditis was 23 months
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TABLE 4. The proportion of CNE in the studied IE
populations
All IE CNE 95%
Episodes Episodes Confidence 
Place Years No. No. (%) Interval
Göteborg 1984–88 161 34 (21) 15–28
Göteborg 1989–96 2561 48 (19) 14–24
Borås 1989–96 70 19 (27) 18–37
Abbreviations: IE  infective endocarditis; CNE  blood culture-
negative infective endocarditis.
1Duke definite and possible episodes only.
TABLE 5. Duke* compared with modiﬁed Beth Israel† criteria
in 116 episodes of culture-negative infective endocarditis
Duke Criteria
Definite Possible Reject Total
Beth Israel Criteria
Definite 5 8 0 13
Probable 7 8 0 15
Possible 6 21 0 27
Reject 2 43 16 61
Total 20 80 16 116
*Reference 11.
†References 20, 28.
TABLE 6. Alternative diagnosis in 16 CNE patients classiﬁed
as reject by the Duke criteria*
Diagnosis No.
Marantic endocarditis 3
Systemic lupus erythematosus 2
Wegener disease 1
Papillary muscle rupture 1
Myxoid degeneration 1
Pneumonia 2
Other (dental infection, lymphoma, etc.) 6
Total 16
*Reference 11.
(mean, 34 mo; range, 0–162 mo). Six of the episodes could
be defined as early prosthetic valve endocarditis (2 mo
after surgery), and 23 as late prosthetic valve endocarditis
(2 mo after surgery).
Noncardiac surgery had been performed less than 90
days before the first symptom of infective endocarditis in
6 episodes. The surgical procedures were hip surgery, neu-
ral decompression, fasciotomy of the thigh, incision of a
vaginal hematoma, urethra dilatation, and drainage of a
peritoneal abscess. Four patients developed infective en-
docarditis during hospital treatment; the reasons for their
initial admission were valvular surgery, ventricular septum
defect repair, coronary by-pass, and childbirth, respec-
tively. In 9 episodes, patients presented with wounds or ab-
scesses. Two patients had postoperative infections after
thoracotomy, 6 had superficial wounds, and 1 had a deep
abscess. One patient had a urinary tract infection preced-
ing the first symptoms of infective endocarditis.
Dental status
In 22 episodes (19%), the patient had visited the den-
tist less than 90 days before the first day of illness (see
Table 8). The dentist examined the patients during 74
episodes and found abnormal dental status in 39 (52%).
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FIGURE 1. Distribution of major and minor criteria in 80
Duke possible episodes.
FIGURE 2. Göteborg, Sweden,
1989–1996: 517 consecutive epi-
sodes of suspected infective endo-
carditis evaluated with the Duke
criteria (CNE  blood culture 
negative-endocarditis).
Cardiac murmurs, heart failure, and embolism
Data concerning heart failure are shown in Tables 8
and 11. In 46 (40%) episodes heart failure was noted at the
start of infective endocarditis therapy, with deterioration in
27 (23%) of the episodes. In another 15 (13%) of the
episodes, heart failure developed during infective endo-
carditis therapy (see Table 11). Data concerning murmurs
are presented in Table 9; 89% of patients presented a car-
diac murmur at admission.
In 19 episodes (16%) clinical embolism was present
at the start of infective endocarditis therapy (see Table 8);
11 of the emboli passed to the central nervous system. In
another 9 (8%) episodes emboli occurred after the initia-
tion of infective endocarditis therapy (see Table 11).
Location
Left-sided infective endocarditis was diagnosed in 94
episodes (aortic valve, 49; mitral valve, 35; combined aor-
tic and mitral valve, 9; and combined aortic and patch in-
fection, 1) (Table 10). One patient had a pacemaker infec-
tion, and 2 patients had mural infections. In the remaining
19 episodes no apparent location was found at echocar-
diography. Transesophageal echocardiography was used
in 6 of these episodes.
Echocardiography
Transesophageal echocardiography was performed
in 39 episodes and transthoracic echocardiography in 106
episodes. Altogether 114 episodes were investigated with
echocardiography during the first week of treatment. The
use of transesophageal echocardiography and transtho-
racic echocardiography was studied especially in the Duke
possible group since transesophageal echocardiography
became available in 1991. Five (38%) of the 13 episodes
with 2 minor criteria were investigated with transesopha-
geal echocardiography, compared with 19 of 24 (79%) in
the 1 major and 2 minor criteria group during this period
(p  0.03).
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TABLE 7. Days with symptoms until hospitalization and start of IE treatment
Median Mean Range
(d) (d) (d)
Symptom duration until hospitalization (n  111)* 10 23 0–247
Time to IE treatment after hospitalization (doctor’s delay) (n  109)† 2 5 0–32
Total symptom duration until IE treatment (n  114)‡ 14 27 0–266
Fever duration until start of IE treatment (n  112)§ 9 16 0–180
Abbreviations: IE  infective endocarditis.
*Five episodes excluded because of nosocomial infection.
†Seven episodes excluded (episodes without IE treatment, 5 episodes with nosocomial IE).
‡Two episodes without IE treatment.
§Missing data in 4 episodes.
TABLE 8. Predisposing factors in 116 episodes of culture-
negative infective endocarditis
(%)
Valvular factors
Prosthetic valve 24
Previous IE 13
Valvular surgery 30
Atherosclerosis 10
Rheumatic fever 14
Congenital heart disease 6
No valvular disease (except IE at diagnosis) 30
Concomitant diseases
Connective tissue disease 9
Diabetes mellitus 10
Malignancy 9
Drug use and medication
Treatment with neuroleptic drugs 2
Habitual alcohol drinker 8
Intravenous drug addict 1
Events preceding start of IE therapy
Embolism 16
Heart failure 40
Visit to the dentist 90 d before first symptom 19
of disease
Noncardiac surgery 3 mo before IE 5
Abbreviations: IE  infective endocarditis.
TABLE 9. Cardiac murmurs (systolic and/or diastolic) 
(n  116)
(%)
Murmur at admission 89
New murmur at admission 37
Changed murmur at admission 7
New murmur during treatment 2
Blood culture, serology, and antibiotic therapy
A median of 3 blood cultures was done (mean, 5;
range, 2–16). The exact number of blood cultures before
infective endocarditis treatment was unknown in 7 pa-
tients. One patient had serologically verified Q-fever 
endocarditis. In 34 (29%) episodes the patients were on
antibiotic treatment, and in another 19 (16%) episodes an-
tibiotic pretreatment was given less than 60 days (mean, 11
d; median, 7 d; range, 1–41 d) before the first blood cul-
ture was done. The median duration of antibiotic treat-
ment in the pretreated episodes was 10 days (mean, 9 d;
range, 1–33 d).
The proportion of episodes with ongoing or previous
antibiotic treatment at the time of the first blood culture in
all CNE episodes was 45% (95% CI 37–55). The propor-
tion of antibiotic pretreatment at blood culture was 45%
(95% CI 24–69) in the definite group, 46% (95% CI 35–57)
in the possible group, and 44% (95% CI 20–64) in the re-
ject group (Duke criteria). The Duke possible group was
further divided into 6 subgroups. Antibiotic pretreatment
at blood culture was present in 43% (17/39) of episodes in
the 1 major and 2 minor criteria group, in 100% (4/4) of
episodes in the 1 major and 1 minor criteria group, in 14%
(1/7) of episodes in the 3 minor criteria group, and in 55%
(15/27) of the episodes in the 2 minor criteria group. There
was no antibiotic pretreatment in the groups with 1 minor
or 4 minor criteria.
Valvular culture was performed in 9 of 16 surgically
removed valves. One valve was culture positive (Capnocy-
tophaga canimorsus). One valve was cultured postmortem
with growth of Klebsiella and E. coli (see Table 11).
Surgery
Surgery data are presented in Table 11. The median
time to surgery from start of infective endocarditis therapy
was 9 days (mean, 15 d; range, 0–40 d). Seventeen patients
underwent early open heart surgery in 18 episodes, with a
male/female ratio of 0.89 (8/9).
Mortality and follow-up
Eight patients (7%) died during infective endocardi-
tis therapy or less then 1 month posttreatment (see Table
11). The median time from start of infective endocarditis
therapy to death was 29 days (mean, 38 d; range, 5–80 d).
One of the deceased was surgically treated. Three patients
had autopsies, and all had PAD-proven endocarditis. Four
of the 8 patients who died were defined as Duke definite,
including the 3 autopsied cases.
Four patients suffered a new episode of culture-
positive infective endocarditis during follow-up. Ninety-
seven of 106 surviving patients had a median follow-up
time of 42 months (mean, 49 mo; range, 1–180 mo).
DISCUSSION
Patients
The rather high proportion of CNE in the studied
population corresponds with studies from Finland (Duke
criteria, definite 23% versus possible 66%) (16), Denmark
(Beth Israel definite and possible 12%) (3), and Sweden
(Duke criteria, definite and possible 23%) (23). A study
from the Netherlands found 1% CNE in the studied infec-
tive endocarditis group (38). This low proportion is due to
selection bias, the participants being collected on the basis
of positive blood cultures. Studies from developing coun-
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TABLE 11. Clinical and diagnostic events and surgery during
IE treatment (n  116)
(%)
Increasing heart failure 36
Embolism during antibiotic therapy 8
Valvular surgery during therapy and 1 mo follow-up 15
Aortic valve surgery 8*
Mitral valve surgery 5†
Aortic and mitral valve surgery 2‡
Removal of pacemaker wire 1
PAD performed at surgery 5§
Valvular culture 9¶
Death during therapy and 1 mo follow-up 7
Autopsy 3
Valvular culture at autopsy 1**
PAD performed at autopsy 3††
Abbreviations: IE  infective endocarditis; PAD  pathologic and
anatomic diagnosis.
*In 2 episodes mechanical valves and in 7 episodes biological valves.
†In 4 episodes mechanical valves and in 2 episodes vegectomy.
‡In both episodes 1 mechanical and 1 biological valve.
§Two episodes of infective endocarditis, 1 myxoid degeneration, 1
sclerosis (not IE), 1 vegetation (later diagnosis of systemic lupus erythe-
matosus.
¶Capnocytophaga caninimorsus was cultured in 1 episode.
**Klebsiella spp and E. coli were cultured in 1 episode.
††Three episodes of IE.
TABLE 10. Location of infective endocarditis determined by
echocardiography, surgery, or autopsy (n  116)
(%)
Aortic valve 42
Mitral valve 30
Aortic and mitral valve 8
Aortic valve and patch infection 1
Mural vegetation 2
Pacemaker wire 1
No exact location 16
tries such as India and Morocco present much higher pro-
portions of CNE (55%-58%) (4, 6). The relatively high rate
of CNE in the cited studies from developed countries does
not support the statement that CNE is a rare diagnosis
(5%) in modern infective endocarditis studies (37). The
low proportion (6.4%) of CNE among Duke definite
episodes in the present study may be an underestimation
due to the classification system.
There was no trend in the annual incidence of CNE
among the patients with infective endocarditis, even
though transesophageal echocardiography and better
blood culturing techniques became accessible during the
study period (see Figure 2). The use of echocardiography
on wide indications may add to a still high proportion of
CNE among infective endocarditis patients even though
the sensitivity and specificity of the method is high (7, 26).
Treatment and suspicion of infective endocarditis on
wide indications probably increase the proportion of
CNE in western countries, but early case detection is im-
portant to attain a low mortality from infective endo-
carditis (3, 20).
The male/female ratio in the CNE episodes (1.0) dif-
fers from the French CNE study (18) by a ratio of 3 (which
may be due to selection bias of the reporting system in the
study) and from other general clinical and population-
based studies of infective endocarditis by a ratio of 1.3–2.5
(3, 6, 8, 16, 25, 35, 38,40). The even sex distribution in our
study corresponds with the series described by von Reyn
(39) and the Duke Endocarditis Service (11).
The median age of all patients in the present study
(67 yr) was higher than that in the French CNE study (18)
(53 yr). The median age in women was even higher (70 yr).
These age and gender differences may be due to the
prospective character of our study, with early diagnostic
procedures in suspected cases of infective endocarditis. An
aged population with a majority of elderly women with
good access to hospital care, as in Sweden during the stud-
ied period, probably contributes to the group of infective
endocarditis patients with an increase of the median age
and a decrease of the male/female ratio
Classification
The modified Beth Israel criteria and the Duke crite-
ria were compared (see Table 5) (11, 39). Only 20 episodes
fulfilled the criteria for Duke definite, and 16 for Duke re-
ject. The small number of Duke definite episodes, although
more than the episodes classified as Beth Israel definite,
may partly depend on strict use of the Duke criteria in pa-
tients who have undergone surgery or died. Valvular cul-
ture and/or PAD were not performed in 4 patients who un-
derwent surgery, showed macroscopic signs of infective
endocarditis, and were classified as possible infective en-
docarditis. Thus the Duke criteria may be insensitive when
used strictly, not accepting macroscopic evidence of infec-
tive endocarditis.
The Duke possible group is the largest, accounting
for 80 (69%) of the 116 CNE episodes. It is heterogeneous,
including patients with a high likelihood of infective endo-
carditis together with patients with a very low likelihood
but with infective endocarditis treatment 4 days and no
other obvious diagnosis. In our study, 39 of the episodes in
the Duke possible group fulfilled 1 major and 2 minor cri-
teria. Authors of a Swiss study (33) estimated the power of
every Duke criterion. The major microbiologic criterion
had the greatest impact (53%), followed by the major en-
docardial criterion (34%), when Duke definite and possible
episodes were distinguished. In CNE the major endocar-
dial criterion is very important in the absence of positive
blood cultures. Only 38 of the CNE episodes in our study
were investigated with transesophageal echocardiography.
This more sensitive method may have been able to detect
more episodes with the major endocardial criterion. The
interobservational variation in echocardiographic investi-
gations also stresses the risk of misclassification (15). Inves-
tigation of immunologic phenomena such as rheumatoid
factor was not done, according to the study protocol. A pos-
itive rheumatoid factor test could have had an impact, clas-
sifying more episodes as Duke definite (33). Neither Cox-
iella burnetii nor Bartonella serology was done routinely as
the incidences of Q-fever and Bartonella endocarditis were
presumed to be low in the studied population.
In 43% (17/39) of the Duke possible episodes with 1
major and 2 minor criteria, ongoing or previous antibiotic
treatment was found at the first blood culture. There was
no significant difference in antibiotic pretreatment in this
group compared with the other studied groups or sub-
groups. Our study did not add support to the suggested
need for a new criterion of antibiotic pretreatment at blood
culture in CNE patients with 1 major and 2 minor criteria
to classify these episodes as Duke definite. It is necessary
to have a larger study group with CNE patients with either
surgical valve replacement or autopsy where PAD and
valvular culture is performed consistently, to study the in-
fluence of antibiotic pretreatment in CNE.
In 27 of the 80 possible episodes, only 2 minor crite-
ria were present (fever 38.0 C and a predisposing heart
condition). Valvular prosthesis, an earlier episode of in-
fective endocarditis, atherosclerotic valves or congenital
heart disorder, and fever were noted. Transesophageal
echocardiography was done (since it became available in
1991) in 5 of 13 patients in the 2 minor criteria group com-
pared with 19 of 24 in the 1 major 2 minor group during
this period (p  0.03). It is too simple to classify patients
with a valvular prosthesis and fever as Duke possible. We
agree with the proposed modifications of the Duke criteria
to increase the specificity of the possible class and that at
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least 3 minor criteria or 1 major and 1 minor criterion are
necessary to classify an episode as possible infective endo-
carditis (24). Transesophageal echocardiography should
be used when diagnosing suspected CNE to distinguish pa-
tients in the possible and reject groups.
Earlier evaluations of the Duke criteria have studied
the sensitivity and the specificity in different patient groups
(9, 11, 17, 34, 36). In our study the Duke criteria were more
sensitive compared with the modified Beth Israel criteria in
identifying the definite episodes (20 versus 13 episodes, re-
spectively). However, it is more useful to compare the mod-
ified Beth Israel criteria definite and probable group (the
latter including patients who did not undergo surgery or
die) with the Duke definite group. This comparison, on the
other hand, shows an increased sensitivity in the Beth Israel
criteria (28 versus 20 episodes, respectively).
In the present study, the modified Beth Israel criteria
distinguish 62 episodes as reject, indicating a better speci-
ficity compared with 16 reject episodes identified with the
Duke criteria. This better discriminating ability is due to
the fact that the Beth Israel criteria disregard the time of in-
fective endocarditis treatment (more or less than 4 d) and
do not require a firm alternative diagnosis to reject infec-
tive endocarditis, which sometimes is impossible in a clin-
ical situation. Studies of the positive predictive value of the
Duke criteria in different study populations are wanted.
We have not calculated the sensitivity and the speci-
ficity of the Duke criteria, as different methods were used
to collect the patients. The alternative diagnosis in 16 re-
ject episodes is presented (see Table 6) just to stress the im-
portance of trying to rule out other important diagnoses in
patients with suspected infective endocarditis (13).
Presentation
The mean duration from the first symptom to admis-
sion was 23 days, which is shorter than in earlier reports
studying CNE (18, 30) (see Table 7). The median time to
admission was considerably shorter, 10 days. A more im-
portant variable is the median time from first symptoms to
infective endocarditis treatment, 14 days in this study. This
is comparable to data from modern studies of infective en-
docarditis in general, with a delay of 11–13 days (3, 20).
Cardiac murmurs and embolism
In 89% of episodes a cardiac murmur was present
(see Table 9). Murmurs have a great influence in prompt-
ing for diagnostic procedures, especially in episodes with a
new murmur, 37% of the cases in our study. A new cardiac
murmur is a major endocardial criterion that is of great im-
portance when classifying infective endocarditis episodes
with the Duke criteria.
In 16% of episodes, embolism preceded attendance
to hospital. More than 50% of these emboli went to the
central nervous system (CNS). CNS emboli often have se-
rious symptoms and may have increased the suspicion of
infective endocarditis in those patients.
Predisposing factors and risk factors
Data concerning earlier prosthetic surgery, earlier in-
fective endocarditis, and location (see Table 8) correspond
with previous studies (18). Alcohol abuse has been pro-
posed as a risk factor in infective endocarditis (1). In the
present study, 8% involved habitual drinkers, a higher pro-
portion than earlier described in the Göteborg study (19).
Homeless alcoholics with suspected or verified body lice
infestation have been associated with Bartonella quintana
infective endocarditis (5). No patient in this study was
homeless or was noted to have body lice. The antibiotic ef-
fect of neuroleptic drugs has been shown in in vitro and in
vivo experiments (22). The influence of neuroleptic drug
treatment in CNE is probably low, as only 2% of the CNE
patients used this medication.
Antibiotic treatment and blood culture
In the present study, antibiotic treatment preceded
blood culture in 45% (95% CI 36–55) of all episodes of
CNE, which corresponds with other studies that report
previous antibiotic treatment in 48%-50% of episodes (18,
23). It differs from a study from Iowa (30), where antibiotic
pretreatment was present at blood culture in 62% (52
episodes) of CNE episodes. We analyzed the episodes with
ongoing and completed antibiotic pretreatment together in
relation to blood culture because the influence of antibiotic
pretreatment has been found to be important (29). The me-
dian time from withdrawal of antibiotic treatment to blood
culture was 7 days in the patients with antibiotic pretreat-
ment, who accounted for 16% of the episodes. The length
of antibiotic pretreatment has been proposed to have a
great influence on inhibition of bacterial growth on blood
culture (37). The median duration of antibiotic therapy was
10 days in our study.
The observation of no difference in the proportions
of antibiotic pretreatment at blood culture between the
Duke definite, possible, and reject groups underlines that
antibiotic pretreatment is not the sole explanation for
blood culture negativity in infective endocarditis. The the-
sis of continuous bacteremia in infective endocarditis as
stated by Beeson and colleagues (2) in the classical work
from the 1940s, where 6 patients with terminal infective
endocarditis disease (5 patients with symptoms for 4–6
months and 1 patient with symptoms for 4 days) were in-
vestigated, needs to be reconsidered when patients with in-
fective endocarditis are diagnosed earlier.
In the beginning of the present study, the blood vol-
ume used for blood culture was rather small (5 mL per
puncture), but it has increased steadily and is now always
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20 mL per culture. In spite of this, there was no significant
change in the proportion of CNE among infective endo-
carditis patients in Göteborg during the years 1989–1996
(blood volume change from 10 to 20 mL). Problems in
blood culturing, such as time from venipuncture to start of
incubation, have not been analyzed but could have had an
impact on the number of CNE patients.
The blood cultures in this study were analyzed in
routine practice and were not always incubated more than
1 week. Fastidious bacteria such as the HACEK (Hemo-
philus aphrophilus, Actinobacillus acinetocomitans, Cardiobac-
terium hominis, Eikenella, Kingella kingae) group and Gran-
ulicatella may have been undetected. -Streptococci may
be inhibited from growing in blood culture by antibiotic
pretreatment (20, 29, 43). The probability of -streptococci
as etiologic agents in some of the episodes of CNE is rather
high, as the patients were on antibiotic treatment in more
than 40% of the CNE episodes.
The FAN media have an antimicrobial neutralizing
effect (41). The observation time in the present study was
too short to evaluate a decrease in the proportion of CNE
episodes after the introduction in 1995. To improve the di-
agnostic accuracy it is important that excised valves in all
cases of suspected infective endocarditis are subjected to
PAD investigation and that the necessary staining is per-
formed to detect, for example, Whipple disease, Bartonella
infection, and Q-fever (31). Tropheryma whippelii and Bar-
tonella have been described as etiologic agents in infective
endocarditis (10, 14, 32). The excised valves in the present
study were not investigated for Whipple disease. New
techniques such as the polymerase chain reaction (PCR)
may improve our understanding of CNE and have been
helpful in diagnosing agents such as Tropheryma whippelii
and Bartonella in valves (12, 21, 42).
Surgery
The rate of early valvular surgery up to 1 month af-
ter the end of antibiotic infective endocarditis treatment
was rather low in the CNE group (14%) and in the Duke
definite group (15%) compared with the previously men-
tioned French study (18). Our study is a prospective study
including all suspected cases, and thus differs from the
French study which is based on reporting from physicians
which may include an increased reporting of surgically
proven cases. The low rate of surgery perhaps reflects the
fact that patients with suspected infective endocarditis
were treated following a scheme which earlier had yielded
good results (20, 28).
Mortality
The mortality during treatment was low (7%) in our
study as a whole compared with earlier series (14%-32%)
(18, 30). The mortality was 20% in the Duke definite
episodes. There was an overrepresentation of Duke defi-
nite episodes among those who died (4/8). More episodes
may have been defined as Duke definite if autopsies had
been done regularly, as only 3 of 8 (38%) patients who died
had autopsies.
Conclusions
The proportion of CNE is about 20% in a large group
of prospectively investigated episodes of infective endo-
carditis in Scandinavia. Fewer than 50% of all episodes of
CNE can be explained by antibiotic pretreatment. Among
116 episodes of CNE studied, 20 were definite, 80 possi-
ble, and 16 reject by the Duke criteria versus 13 definite,
15 probable, 27 possible, and 61 reject by the modified
Beth Israel criteria. The Duke criteria probably both un-
derestimate the real frequency of definite CNE episodes
and overestimate the frequency of possible CNE episodes.
This study supports the importance of performing PAD
and valvular culture in every surgically treated episode or
autopsy of suspected infective endocarditis, especially in
episodes that are blood culture negative, to refine the di-
agnosis and treatment of infective endocarditis.
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Bartonella and Coxiella Antibodies in 334
Prospectively Studied Episodes of Infective
Endocarditis in Sweden
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Bartonella spp. have been identified as aetiological agents in culture-negative infective endocarditis (IE). Coxiella burnetii may
cause chronic Q-fever with endocarditis. 334 blood samples collected from 329 patients (334 episodes) with IE diagnosed between
1984 and 1996 in Go¨teborg, Sweden, were investigated for antibodies to Bartonella spp. and C. burnetii. 71 of the episodes (21%)
were blood culture negative. A microimmunofluorescence assay revealed immunoglobulin G (IgG) antibodies to Bartonella in 13
of the culture verified episodes and in 2 of the culture-negative episodes. Three of the patients had IgG antibodies to ]/200 in the
blood culture-verified group, but none had a titre ]/800, the cut-off level for Bartonella endocarditis. One patient had elevated
antibodies to C. burnetii, diagnosing chronic Q-fever endocarditis. In conclusion, serologically verified Bartonella endocarditis is
not prevalent in western Sweden and Q-fever endocarditis is rare.
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INTRODUCTION
Negative blood cultures in suspected infective endocarditis
(IE) are still a problem, although diagnostic techniques such
as blood culture and echocardiography have improved. The
prevalence of blood culture-negative infective endocarditis
(CNE) is estimated to be 20% in series with IE from
northern Europe (1/3). Coxiella burnetii and Bartonella
species have been diagnosed as causative agents by valvular
culture, blood culture, polymerase chain reaction (PCR),
histological testing and/or serological tests in patients with
CNE (4).
Bartonella quintana causes trench fever. Rats have been
proposed as the reservoir (5), but humans are the only
proven hosts. The body louse is the vector of the disease. The
last Swedish case was described in 1945 (6). Recent
investigations have reported the infection with B. quintana
mainly in homeless patients with CNE (7/9). Antibodies to
B. quintana have been found among homeless people in
France and the USA, and in refugee camps in Burundi (10/
12). Bartonella quintana has also been described causing
bacillary angiomatosis in immunocompromised hosts.
Bartonella henselae is supposed to cause cat-scratch
disease (CSD), which is characterized by a skin lesion after
a cat scratch or cat bite and regional lymphadenopathy.
Bartonella henselae has been detected in patients with CNE,
bacillary angiomatosis or peliosis hepatitis in immunocom-
promised hosts (13). The reservoir of the disease is probably
the cat. The infection may be spread directly from cat to
human or indirectly via a vector (14). The cat flea
(Ctenocephalides felis) may be such a vector (15). Genotypic
variation of B. henselae has been proven; serotype ‘Mar-
seille’ has been isolated from patients with endocarditis and
CSD. Antibodies to this serotype have been shown in CSD
patients seronegative to B. henselae (16, 17).
Q-fever, a rickettsiosis caused by C. burnetii, is a zoonosis
diagnosed worldwide. Coxiella burnetii is usually transmitted
as an inhaled aerosol of parturient fluid from infected
animals. The bacteria may survive for a long time in areas
where animals have been present and the wind may transmit
the bacteria to humans. (18). IE is the most severe form of
chronic Q-fever sometimes diagnosed in CNE patients. In
Sweden sporadic cases of domestic Q-fever have been
reported (19, 20). Seroepidemiological studies in humans
have revealed antibodies to C. burnetii from all over Sweden
(21, 22).
There are no reported cases of Bartonella or domestic Q-
fever endocarditis from Sweden and no earlier reports about
serological testing for antibodies to Bartonella and C.
burnetii in a prospectively collected series of IE. The aim
of this study was to find undiagnosed cases of Bartonella or
Q-fever endocarditis in a prospectively collected group of
patients with IE.
MATERIALS AND METHODS
IE has been prospectively studied since 1984 at the Department of
Infectious Diseases, Sahlgrenska University Hospital, Go¨teborg,
Sweden (23, 24), in a non-randomized descriptive study of con-
secutive patients with suspected IE. A study protocol with uniform
antibiotic treatment regimens, clinical evaluation procedures and
collection of specimens was used. The clinic is a tertiary referral
centre in western Sweden, which also serves as a secondary referral
centre for the population in Go¨teborg, a city with about 600,000
inhabitants situated on the west coast of Sweden. 750 patients were
included in the study during 1984/1996. Blood samples were
collected by venepuncture on inclusion of the patient in the study.
Then, 1/2 ml of serum was separated and stored refrigerated
(/708C). Sera from patients included in the study between 1984 and
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1988 classified as reject IE according to the modified Beth Israel
criteria (23) were discarded in 1996. In addition, some of the samples
were destroyed during storage. The episodes with treated (IE) were
further studied and classified according to the Duke criteria (25).
One serum sample from each IE patient was analysed to find
antibodies to B. quintana, B. henselae and C. burnetii. Bartonella
quintana, Oklahoma strain, B. quintana, Marseille strain, isolated
from a French patient (ATCC 49882T); B. henselae, strain Marseille,
B. henselae, Houston strain, were used as antigens. The bacteria
between the fourth and seventh passage in a human endothelial cell
line (ECV) were harvested, pelleted and used as crude antigen in a
microimmunofluorescence (MIF) assay (26, 27). The current cut-off
levels for diagnosis of Bartonella endocarditis have been estimated to
be ]/800 immunoglobulin G (IgG) antibodies with a positive
predictive value (PPV) of 0.955 in patients with endocarditis (28).
Patients with titres between 50 and 200 may have been in contact
with cats and have a residual positive serology (27). IgA and IgM
antibodies were not determined as they are not exhibited in patients
with Bartonella endocarditis (28).
Q-fever serology was performed with an MIF assay to identify
antibodies to C. burnetii antigen (29). The cut-off level for a
diagnosis of chronic Q-fever was phase I IgG ]/800 with a PPV of
0.98.
RESULTS
Sera from 71 episodes of CNE (12 definite, 52 possible, 7
reject; Duke criteria) in 70 patients and from 263 episodes
with culture-verified IE (171 definite, 69 possible, 23 reject)
in 259 patients were examined (Table I). In total, sera from
334 episodes in 329 patients were examined.
Q-fever
Coxiella burnetii serology consistent with Q-fever endocar-
ditis with phase I antigen IgG 1000 was detected in 1 patient.
Bartonella
Bartonella antibodies were found in 15/334 (4.5%) of the
episodes (Table I). Cross-reacting antibodies between B.
quintana and B. henselae were detected in 8 of these 15
seropositive episodes. Three patients with B. henselae anti-
body levels IgG ]/200 were from the blood-culture positive
group and were recruited to the study during the 1980s. Case
number 1, a previously healthy 53-y-old man who had a
Streptococcus millerii IE (Duke definite), fully recovered.
The B. henselae and serotype ‘Marseille’ IgG antibodies
were 200. Case number 2, an 82-y-old man who lived in a
sheltered accommodation, suffered from prostatic cancer
and had had a myocardial infarction 3 times. He acquired an
Enterococcus IE (Duke definite) and recovered completely
after antibiotic treatment. Bartonella henselae antibodies
were 200. Case number 3, a 67-y-old man with alcohol abuse,
acquired an Enterococcus faecalis IE (Duke definite). He
underwent acute valvular surgery and recovered. The B.
henselae and serotype ‘Marseille’ IgG antibody titre was
400.
Case number 4, the only patient with CNE, had slightly
increased levels of B. henselae antibodies (IgG 100). He was
a 74-y-old man with chronic renal disease. He had no
previous antibiotic treatment on blood culture. Echocardio-
graphy demonstrated a little firm vegetation on the aortic
valve. He had fever and a new systolic murmur on heart
auscultation. The episode was classified as possible by the
Duke criteria. He recovered completely after antibiotic
treatment.
No data was available about contact with cats or signs of
cat-scratch disease in any of these patients.
DISCUSSION
This screening of sera from 334 episodes of IE did not find
any undiagnosed cases of Q-fever or Bartonella infection.
The only patient with increased levels of phase I antibodies
to C. burnetii had an already diagnosed and treated Q-fever
endocarditis, probably acquired in Crete, Greece (30, 31).
Among the studied episodes 183 were classified as definite
by using the Duke criteria. 12 of these episodes were CNE
(7%) (Table I).
The sera with antibodies to Bartonella between 200 and
400 were to be found in the blood culture-positive episodes
of IE. However, the antibody levels did not reach the cut-off
for IE, which is 800 (28). There were no data in their records
about cat contact or body lice. One of these 3 patients was a
habitual drinker, but he lived in tidy conditions. The
population of homeless people in Go¨teborg is quite small
(32, 33) and none of the investigated patients was homeless.
Body lice are seldom found in Swedish patients. It is not
probable that the patients were infected with B. quintana,
although it is not necessary to have an antibody response
despite growth of B. quintana on blood culture (34). In
another Swedish study PCR identified B. quintana in a liver
biopsy from 1 patient. In another patient B. quintana was
detected in the myocardium but the antibody response was
directed to B. elizabethae. The presence of cross-reacting
antibodies between different Bartonella species raises the
hypothesis of the presence of antigenic variants of B.
quintana and B. henselae (35). Two different genotypes of
B. henselae, which may affect the antigenic expression, have
been isolated in German cats and humans (36, 37).
The elevated antibody response to Bartonella in the group
studied, 4.5% (95% confidence interval 2.3/6.7%) (15/334),
indicates an earlier contact with cats infected with B.
Table I. Distribution of Bartonella antibodies among 334 episodes of
infective endocarditis evaluated according to the Duke criteria
Definite Possible Reject
Blood-culture negative n/12 n/52 n/7
Bartonella/800 0 0 0
200/400 0 0 0
50/100 0 2 0
Blood-culture positive n/171 n/69 n/23
Bartonella/800 0 0 0
200/400 3 0 0
50/100 9 1 0
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henselae or the presence of cross-reacting antibodies to B.
elizabethae. Antibodies to B. elizabethae have been detected
in Swedish cats, with the highest prevalence in southern
Sweden (38). Bartonella (including B. elizabethae) antibodies
have previously been found in 4% of Swedish blood donors
and in 8.3% of patients with suspected Bartonella infection
from Sweden (35). It may be concluded that Q-fever rarely
causes IE in western Sweden and that no cases of serologi-
cally undiagnosed Bartonella IE were found. Q-fever serol-
ogy should be done in all patients with CNE, since domestic
Q-fever has been diagnosed and travelling abroad is com-
mon. CNE patients with a history of homelessness, contact
with body lice or owners of cats should be tested for
Bartonella antibodies. If valvular surgery is performed,
culture, PCR and histology should be done of the excised
valves.
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Abstract  
The aims of this study were to investigate whether serologically documented Chlamydophila 
pneumoniae (Cp) infection is more prevalent in patients with blood culture negative 
endocarditis (CNE) than in those with blood culture positive endocarditis (CPE), and to 
investigate if increased levels of Cp antibodies may indicate a risk factor for infective 
endocarditis (IE), and if there might be any difference between men and women in this 
respect.  
Cp antibodies were analyzed by a microimmunofluorescence technique in 71 CNE episodes 
and 216 CPE episodes as well as in a randomly selected population control group of 70-year 
olds. The proportion of Cp IgG and IgA antibodies were compared in specimens from CPE 
and CNE episodes. No significant differences were found. Cp antibodies were compared in 
specimens from IE episodes and population controls. The results for men were Cp IgG≥512: 
33% vs. 26 % of the controls, (aOR 1.37 [0.83-2.27]) and Cp IgA≥64: 45 % vs. 31% (aOR 
1.80 [1.12-2.91]). The results for women were Cp IgG ≥512: 32% vs. 17%, (aOR 2.21 [1.32-
3.70]) and Cp IgA ≥64: 32% vs. 10% (aOR 3.98 [2.26-7.01]). 
Increased levels of Cp IgA and IgG indicating infection with Cp were not found to be 
significantly different in CNE and CPE. High levels of Cp IgA were found more often in IE 
patients than in controls.  
 
Key Words: Infective endocarditis, valvular disease, Chlamydophila pneumoniae
 
Introduction 
Patients with valvular disease are prone to 
acquire infective endocarditis (IE) (1) and 
valve calcifications are prevalent as a 
cause of valvular disease (2). 
Chlamydophila pneumoniae (C. 
pneumoniae) has been suggested to be 
associated with arteriosclerosis and  
 
valvular disease, but its role in IE is 
unclear (3-10) Blood culture negative 
endocarditis (CNE) affects 10-20 % of 
patients with IE (11, 12). One of the 
microbes proposed as a cause of CNE is C. 
pneumoniae (13, 14).  
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The aims of this study were: 
1. To investigate whether serologically 
documented C. pneumoniae infection is 
more prevalent in patients with CNE than 
in those with blood culture positive 
endocarditis (CPE).   
2.To investigate if increased levels of C. 
pneumoniae antibodies may be a risk 
factor for IE and if there might be any 
difference between men and women in this 
respect. 
Study groups and methods 
Study groups 
IE has been prospectively studied since 
1984 at the Department of Infectious 
Diseases, Sahlgrenska University Hospital, 
Göteborg, Sweden (1), a secondary and 
tertiary referral center in southwest 
Sweden. It is an ongoing non-randomized, 
descriptive study of consecutive patients 
with suspected endocarditis. The protocol 
includes clinical evaluation and collection 
of specimens. The protocol does not 
include questions about smoking, lung 
disease, hypertension and obesity. In all 
750 patients were diagnosed with 
presumptive endocarditis between the 
years of 1984-1996. Blood samples were 
collected at inclusion and sera were stored 
at -70°C. Sera from patients included in the 
study between 1984 –1988, but later 
classified as Reject according to the 
modified Beth Israel criteria for IE, were 
discarded (1). Some samples were 
destroyed during storage.  
In all, 314 episodes in 308 patients 
diagnosed as IE were analyzed with 
Chlamydia serology. The episodes were 
classified according to the Duke criteria; 
Duke Definite, Possible or Reject (15). 
Patients who did not qualify according to 
the Duke criteria were excluded from 
further analysis (27 episodes). Blood 
specimens for serological analysis were 
taken at the start of IE therapy in all but 
four patients. Data about sex and age  
distribution in CPE and CNE episodes are 
shown in Table I. 
 
Table I. Age and the sex distribution in blood-
culture positive endocarditis (CPE), blood-culture 
negative endocarditis (CNE) and in all studied 
cases of infective endocarditis (IE). 
  
All  patients 
 
Men 
 
Women
CNE: mean age, 
range [] years. 
(number) 
62.0  
[26-84].  
(71) 
62.3  
[41-83].  
(38) 
61.6  
[26-84]. 
(33) 
CPE mean age, 
range ([]) years. 
(number) 
58.7 
[20-89]. 
 (216) 
56.3 
[20-89]. 
(122) 
61.7  
[18-87].
 (94) 
IE mean age, 
range []years, 
(number)  
59.5 
[20-89].  
(287) 
 57.7  
[20-89]. 
(160) 
 61.7  
[18-87].
(127) 
 
The Longitudinal Gerontological and 
Geriatric Studies in Göteborg, Sweden is a 
population study, which was initiated 
1971/72 in Göteborg. From this study a 
sample of 1148 70-year old men and 
women were randomly selected in the 
Göteborg area (16), sera from  a sample 
from this group (102 men and 142 women) 
were analyzed for C. pneumoniae 
antibodies. In 1992, another randomly 
selected sample of 753 70-year old people 
were included in the study and sera from a 
sample from this later group (76 men and 
106 women) were also analyzed for C. 
pneumoniae antibodies (17). 
 
Methods 
Serology was analyzed using a modified 
microimmunofluorescence technique (18). 
Sera were diluted 1:16 (for IgM and IgA 
antibodies) and 1: 32 (for IgG antibodies) 
in phosphate buffered saline (PBS), pH 
7.4, and tested for IgG, IgA and IgM 
antibodies on 21 well antigen slides 
containing elementary body preparations 
of C. psittaci, C. pneumoniae and 
Chlamydia trachomatis in each well  (Lab 
Systems Oy, Finland), according to an 
earlier report (18). Sera positive in 
screening tests for IgG were rediluted and 
tested in doubling dilutions. Sera positive 
in screening tests for IgA and/or IgM were
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 mixed with Gullsorb (Gull Laboratories, 
USA) at a dilution of 1:16 to remove all 
IgG and then titrated in doubling dilutions 
with PBS (19).  The same investigator 
blinded to case/control status read all 
slides. Control sera routinely used in the 
laboratory was included in every test run 
and tests were only accepted if the control 
sera titers were within one titer step of the 
mean earlier calculated. The last dilution 
step to give a specific fluorescent pattern 
was reported as the reciprocal titer (18). A 
C. pneumoniae titer of IgG antibodies 
≥512 and a C. pneumoniae IgA ≥64 
antibody titer were chosen as cut-offs for 
presumptive acute reinfection or persistent 
infection (19).  
Statistics  
The probability of C. pneumoniae IgG 
≥512 and C. pneumoniae IgA ≥64 as a 
function of age, gender (men=0, 
women=1) and 0-1 variable CNE was 
estimated with help of the logistic 
regression analysis. The probability of C. 
pneumoniae IgG ≥512 and C. pneumoniae 
IgA ≥64 at the age of 70 years (the age of 
the individuals in the control group) can be 
calculated as 1/(1+exp (-S), where S is a 
linear combination of the following type. 
ß0+ ß 1· 70 + ß 2· 1 + ß 3·0.  The number 
70 represents age, 1 female and 0 presence 
of CNE. The last two variables may be 
changed depending upon the group of 
patients studied. The standard deviation 
(SD) of the linear combination was 
estimated by use of the matrix of 
covariance. In the pooled group of CPE 
(CNE=0) and CNE (CNE=1) was the 
logistic model used without the CNE 
variable. Sex differentiated analogous 
calculations were done on the control 
group. The variables age and sex were not 
included in this calculation. An adjusted 
odds ratio (aOR), taking age into account 
by use of the multiple logistic regression, 
was used comparing the presence of C. 
pneumoniae IgG ≥512 and IgA≥64 in the 
patient group CNE =0 and CNE=1 versus 
controls of the same sex and in the CNE=1 
group versus CNE=0 group. Confidence 
limits (95% level) are given in brackets [CI 
95%]. Values of quantitative variables 
were expressed as means and range (in 
brackets []). 
Results  
A comparison of C. pneumoniae 
antibodies in CNE and CPE patients  
CPE and CNE episodes were compared 
taking age into account (Figure 1 and 2). 
The results for men were IgG ≥512 (CPE 
30% vs. CNE 42% (aOR 1.69 [0.84-3.33])) 
and for IgA ≥64: (CPE 41% vs. CNE 53% 
(aOR 1.61 [0.83-3.13])).  
The results for the women were: IgG 
≥512 (CPE 29% vs. CNE 40% (aOR 1.69 
[0.83-3.45])) and IgA ≥64 (CNE 29% vs. 
CPE 40% (aOR 1.61 [0.79-3.23])). 
A comparison of C. pneumoniae anti-
bodies in IE patients and population 
controls 
IE episodes with an estimated prevalence 
of C. pneumoniae antibodies at the age of 
70 years were compared with controls 
(Figure 1 and 2). The results for men were 
C. pneumoniae IgG≥512: (33% vs. 26 % 
of the controls, (aOR 1.37 [0.83-2.27])) 
and Cp IgA≥64: (45 % vs. 31% (aOR 1.80 
[1.12-2.91])). The results for women were 
C. pneumoniae IgG ≥512: (32% vs. 17%, 
(aOR 2.21 [1.32-3.70]) and Cp IgA ≥64: 
32% vs. 10% ((aOR 3.98 [2.26-7.01])).  
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Proportions of C. pneumoniae IgG ≥ 512 in the 70-year old control group compared with the estimated 
probability (percent) at the age of 70 years in infective endocarditis patients (IE). Blood culture positive 
endocarditis (CPE) and blood culture negative endocarditis (CNE) episodes were compared and the odds 
ratios OR were age adjusted 
Proportions of C. pneumoniae IgA ≥64) in the 70-year old control group compared with the estimated 
probability (percent) at the age of 70 years in infective endocarditis patients (IE). Blood culture positive 
endocarditis (CPE) and blood culture negative endocarditis (CNE) episodes were compared and the odds ratios 
(OR) were age adjusted 
 
Discussion 
No significant differences were seen in the 
proportions of episodes with high levels of 
C. pneumoniae antibodies when comparing 
CNE and CPE episodes and consequently, 
the study does not support the hypothesis 
of C. pneumoniae as a cause of blood 
culture negative endocarditis. 
The C. pneumoniae antibody levels in IE 
patients were compared with the results 
from the antibody determination from the 
control population. We found a significant 
difference with increased C. pneumoniae 
IgG and IgA antibody levels in the female 
IE cases compared to the female controls. 
There were also increased C. pneumoniae 
IgA antibody levels in IE men compared to 
control men.  The results should however 
be judged with caution. Although adjusted 
for age and sex the results were not 
adjusted to smoking, hypertension and 
obesity, proposed confounding factors in 
studies of aortic valve sclerosis (20, 21) 
To our knowledge this is the first 
seroepidemiological study of C. 
pneumoniae in IE and in a control 
population. Antibodies to Bartonella were 
looked for but not found in the IE episodes 
and it is unlikely that cross-reacting 
antibodies could have caused the increased 
proportions of C. pneumoniae antibodies 
(22) 
The specimens from the IE cases were 
collected during 13 years. About half of 
the specimens from the control group were 
collected 10 years earlier than the first 
specimens from an endocarditis patient. 
However, an ongoing epidemic that could 
have affected the controls seems not to 
have negated the significant differences 
found.  
There is no validated reference test 
universally agreed upon for the diagnosis 
of persistent C. pneumoniae infection.  The 
microimmunofluorescence test, considered 
to be the gold standard, is technically 
complex and diagnostic criteria can differ 
from laboratory to laboratory (23). IgG 
antibodies can be expected to be detected 
in serum for many years after an infection 
and serum IgG of ≥512 may demonstrate a 
possible chronic infection, but may of 
course also indicate recent infection with 
the bacterium. It might have been possible 
to distinguish between these two types of 
infection with analysis of sequential sera.  
IgA antibodies have a short half-life (about 
one week) and therefore it is thought that 
high levels of this immunoglobulin should 
be more indicative of an acute reinfection 
or a sustained infection. We used humoral 
IgA as a marker of persistent infection, 
although it is not a universally accepted 
criterion, and chose IgA ≥ 64 as a cut-off 
level because this level of antibody is not 
usually found in healthy, uninfected 
individuals (23, 24).  
The association between C. pneumoniae 
antibodies and aortic valve sclerosis is not 
proven (6). C. pneumoniae has been 
detected in calcified aortic valves with 
immunohistochemistry and / or polymerase 
chain reaction (4, 5, 7, 25).  In other such 
studies, C. pneumoniae have not been 
found(6, 8, 10). The relevance of raised C. 
pneumoniae IgG and IgA antibodies in 
serum and the finding of the bacteria in 
heart valves is not fully understood (6, 7, 
26). Also it is uncertain whether the results 
of antibody tests in our patients mirror true 
Chlamydophila infections in heart valves, 
since we did not have the opportunity to 
study tissues from our patients. .  
The men in all groups had higher 
proportions of IgG and IgA antibodies than 
women, a finding that is consistent with 
other serological studies (27-29). The 
reason for this is unknown.  
Increased levels of C. pneumoniae IgA 
and IgG antibodies may be risk factors in 
women with infective endocarditis; men 
demonstrate a significant increase only of 
IgA. C. pneumoniae has been found in 
atherosclerotic lesions and it is possible 
that either this bacterium could be an 
innocent bystander or a co-pathogen in the 
pathogenesis of endocarditis. The study 
does not support the hypothesis of C. 
pneumoniae as a cause of blood culture 
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negative endocarditis. Future studies are 
necessary to establish a gold standard for 
the diagnosis of suspected C. pneumoniae 
infection in valves.   
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Abstract 
We analyzed data from patients with infective endocarditis (IE) reported to the Swedish 
endocarditis registry during the 10-year period 1995-2004. The patients were cared for at all 
29 Departments of Infectious Diseases in Sweden. We estimated the prevalence of blood 
culture negative endocarditis (CNE) and described and analyzed data with special attention to 
antibiotic treatment.  During the 10-year period, 2509 IE episodes (78% Duke definite) were 
identified in 2410 patients.  
Three hundred and four (12%) CNE episodes were found, of which 42 % were women. The 
number of Duke Definite CNE episodes was 83. Fatal outcome occurred in 10.3  % of all IE 
episodes and in 5 % of the CNE episodes. The risk of dying was significantly increased in 
female (9%) compared to male CNE episodes (2%), OR 5.5. Two hundred and sixty-one 
episodes (88%) received beta–lactam antibiotics and 249 episodes (84%) received 
aminoglycoside therapy. The mortality was significantly decreased in episodes with 
aminoglycoside therapy (3%) vs. episodes without aminoglycoside therapy (13%), aOR 0.23.  
 
Key Words:  Blood culture negative infective endocarditis, antibiotic therapy, epidemiology, 
Sweden 
 
 
Background 
Diagnosis and treatment of patients with 
blood culture negative infective 
endocarditis (CNE) is a challenge for most 
clinicians. CNE is found in 8-54% (1-5) of 
infective endocarditis (IE) cases (IE). 
Diagnostic criteria, clinical settings and the 
health care organization are important 
factors for the estimated prevalence of 
CNE. To our knowledge there are no 
studies on antibiotic treatment in CNE. 
The objectives of this study, using data 
from a national registry for infective 
endocarditis, were: 
1. to estimate the proportion of patients 
with CNE among  Swedish IE patients , 
2. to describe and analyze data from 
CNE patients regarding demography, 
predisposing factors and clinical features,  
3. to describe the antibiotic treatments 
used in the CNE patients in relation to 
mortality and relapse. 
Abbreviations  
Blood culture negative endocarditis  CNE 
Blood culture positive endocarditis  CPE 
Infective endocarditis  IE 
Intravenous drug use  IVDU 
Native valve endocarditis  NVE 
Odds ratio OR 
Prosthetic valve endocarditis PVE 
Transesophageal echocardiography TEE 
Transthoracal echocardiography TTE 
 
 
 
 
2  
Patients and methods 
In 1995 a national registry collecting data 
about IE patients was established in 
Sweden (6), organized by the Swedish 
Society for Infectious Diseases. All 29 
Departments of Infectious Diseases in 
Swedish hospitals participate in registering 
data from patients with diagnosed IE.  
Study design 
The patient’s physician filled in a 
standardized questionnaire at the time of 
the patient’s hospital discharge. The form 
includes questions about the patient’s age, 
sex and predisposing factors such as 
history of heart valvular disease, 
intravenous drug use (IVDU) or prosthetic 
heart valve (PV). The form also includes 
data about the current episode of IE, length 
of hospital stay, patient’s and doctor's 
delays, symptoms and signs, blood culture 
results, echocardiography, treatment and 
outcome. The form does not report 
Bartonella and /or Coxiella burnetti 
serology results. At the follow-up visit, the 
physician filled in a second form 
answering questions about morbidity and 
mortality during follow-up. Data from the 
questionnaires were entered into a 
computerized database and categorized 
according to the Duke criteria (7). The 
Swedish Society of Infectious Diseases in 
2002 published the first Swedish 
guidelines for treatment in IE These 
guidelines were supplemented in 2004 by 
recommendations regarding therapy in 
cases with CNE (8). 
Definitions  
CNE is defined as an episode of IE with 
absence of growth in blood culture and 
classified as Duke definite or possible (7).  
Mortality is defined as a death registered 
in form one. 
Possible relapse of IE is defined as a new 
event of IE during the 6 months after 
completed IE treatment.  
Surgery is defined as cardiac surgery 
during  
the period of parenteral antibiotic 
treatment. 
The first day of an episode is defined as 
the first day of intravenous antibiotic 
treatment. 
Blood cultures  
The local hospital departments of 
microbiology analyzed the blood cultures. 
The automated blood culture systems most 
often used in Sweden during this period 
were the Bac-T Alert and BACTEC 
systems. The blood was incubated for 7-10 
days before test results were answered as 
culture negative. 
Statistics 
Values for quantitative variables were 
expressed as means, medians and range (in 
brackets []). Odds ratio(s) (OR) were 
calculated with 95% confidence limits 
[95% CI] or exact confidence limits when 
needed (StatCalc). Adjusted odds ratios 
were calculated using the multiple logistic 
regression analysis (EpiInfo-6). A two-
tailed test was calculated with a 
significance level of 0.05; Yates correction 
and Fishers exact test were used when 
appropriate. 
Results 
Proportion of CNE among Swedish IE 
patients 
During the ten-year study, 2,546 IE 
episodes were registered. We excluded 
thirty-seven episodes because of 
duplicates, scarcity of data, blood cultures 
not done or classified as rejected by the 
Duke criteria. Data from the remaining 
2,509 treated episodes (2,410 patients) 
were analyzed in the study. Three hundred 
and four episodes (301 patients) were CNE 
and 2,205 episodes (2,109 patients) were 
blood culture positive endocarditis (CPE). 
The proportion of CNE was calculated as 
304/2,509 12% [95%CI 9-15%]. One 
thousand nine hundred and fifty-two IE 
episodes fulfilled Duke definite criteria 
and 83 of these episodes had CNE. The 
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proportion of Duke definite CNE episodes 
was 83/1,952, 4.2%[95%CI 3.6-5.0]. 
Clinical features and predisposing 
factors in CNE patients 
Data are presented in Table 1 and 2. 
Table 1. A comparison of demographic and clinical 
features in 2509 blood culture negative and blood 
culture positive episodes of infective endocarditis 
 Blood  
culture  
negative 
(n=304) 
Blood  
culture 
positive  
(n=2205) 
OR  
[95%CI]  
 
Females  
127 (42%) 764 (35%) 1.35  
[1.05-1.74] 
Age in 
years, 
median and  
range[ ] 
68  
[17-89] 
66  
[14-100] 
- 
Valvular 
disease 
111  
(37%) 
884 
(40%) 
0.86  
[0.67-1,11] 
Prosthetic 
valve 
57 (19%) 394 (18%) 1.07 
[0.77-1.46] 
Previous 
endocarditis 
32 (10%) 218 (10%) - 
Injection 
drug use 
10 (3%) 267 (12%) 0.25 
[0.12-0.48] 
Aortic valve 
 infection 
151(50%) 837 (38%) 1.61 
[1.26-2.07] 
Mitral valve 
 infection 
89 (29%) 754 (34%) 0.80  
0.61-1.04 
Aortic and  
mitral valve 
infection 
20 (7%) 167 (7%) - 
Tricuspid  
valve 
infection 
15(5%) 246 (11%) 0.63  
[0.35 -1.11] 
 
Duke 
criteria  
(Definite / 
Possible) 
83  
(27 %) 
/221 
 (73 %) 
1869  
(85 %) 
/336  
(15 %) 
- 
Vascular  
phenomena  
(emboli) 
63 (21%) 770 (35%) 0.49 
[0.36-0.66] 
The male-female ratios were 1.39 
(177:127) in CNE and 1.89 (1441:764) in 
CPE Acute surgery was performed in 46 
(15 %) of the CNE patients (median day 
12, range [0-75]), as compared to 453 
(21%) of the blood culture positive IE 
(CPE) patients on (median day 11 range 
[7-68]). 
Two of the CNE patients (4%) and 37 of 
the CPE patients (8%) who underwent 
surgery died.  
 
Table 2.A comparison of echocardiographic 
findings, treatment and follow up in blood culture 
positive and negative patients 
 Blood 
culture 
negative 
n=304 
Blood 
culture 
positive 
n=2205 
OR  
[95%CI]  
Echocardio-
graphy,  
300  
(99%) 
2189  
(99%) 
- 
TEE 247  
(82%) 
1717  
(78%) 
1.23  
[0.90-1.69] 
TTE 201 
(66%) 
1527 (69%) 0.87 
[0.67-1.13] 
New 
dehiscence 
of prosthetic 
valve 
10 
 (3%) 
89  
(4%) 
0.81 
[0.39-1.62] 
 
Vegetation 236  
(78%) 
1512 
 (69%) 
1.59 
[1.19-2-14] 
Abscess 10 (3%) 155 (7%) 0,45 
[0.22-0.89] 
Mean in-
hospital time 
(days) 
32 34 - 
Acute 
surgery  
46 / 2971
(15%) 
453/ 21522 
(21%) 
0.69  
[0.49-0.97] 
Mortality  14 (5%),  246 (11%),  0.38 
[0.21-0.68] 
Relapse 3 / 152   
(2 %) 
23/ 1116 
(2%) 
- 
Deceased 
during 
follow up 
4 /152 
 (3 %) 
39/1116 
 (3.5%) 
 
- 
1. Missing data about antibiotic treatment in seven 
episodes 
2. Missing data about antibiotic treatment  in 53 episodes 
Mortality during treatment was 10.3 % in 
all IE-episodes (CNE and CPE included) 
over the ten-year study period (1995-
2004). Fatal outcome occurred in 14 CNE 
patients (5% of the episodes) as compared 
to 246 CPE patients (11% of the episodes) 
0.38 [95%CI 0.21-0.68]. The mortality in 
CNE male episodes was 3/177 (2 %) vs. 
CPE male episodes 149/1441 (10%), OR 
0.15 [95%CI 0.03-0.45]. The mortality in 
CNE female episodes was 11/127 (9%) vs. 
97/764 (13%) in CPE female episodes, OR 
0.6 [95%CI 0.32-1.30]. Fatal outcome 
during treatment occurred in 11/127 (9%) 
of the female CNE episodes vs. 3/177 (2%) 
in male CNE episodes, aOR 5.59 [95%CI 
1.40-31.2] (adjusted for age and 
aminoglycoside treatment).  
In 152 (50.0%) of the CNE episodes and 
in 1,116 (51 %) of the CPE episodes a 
follow-up Case Report Form (CRF) was 
completed.  Time to follow-up was mean 
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96 days in CPE episodes and mean 98 days 
in CNE episodes. A comparison between 
blood culture negative native valve 
endocarditis (NVE) and prosthetic valve 
(PVE) are presented in Table 3. Acute 
surgery was performed in 13% NVE 
episodes as compared with 21% in PVE 
episodes. Death during treatment occurred 
in 3% of the NVE episodes vs. 11% of the 
PVE episodes.  
Antibiotic therapy in CNE  
Data are presented in Table 4. In the two 
hundred and ninety-seven episodes the 
patients received a cell wall–active 
antimicrobial drug for a median of 28 days 
and an aminoglycoside was added for a 
median 14 days in 84% of these episodes.  
The antibiotics used included Penicillin G, 
ampicillin, oxacillin, cephalosporin and 
carbapenem antibiotics in 261 (88%) 
episodes, vancomycin in 81 (27%) 
episodes and sequential therapy with these 
antibiotics in 57 episodes. Rifampicin 
treatment was administered in twelve 
episodes: Eight NVE episodes and four 
PVE episodes. In 48 (16%) episodes no 
aminoglycoside therapy was given. Fatal 
outcome occurred in eight of the episodes 
(3%) that received amino-glycosides as 
therapy for IE versus six of the episodes 
(13%) who did not receive amino-
glycosides, aOR 0.23 [0.08-0.85] p=0.03 
(adjusted age and sex). Eight patients with 
blood culture negative NVE and six PVE 
patients, all who died are described in 
Tables 5 and 6. In NVE were 7/8 and in 
PVE were 4/6 of the dead patients females.  
 
Relapses 
Three CNE patients had a new IE during 
follow-up within the first 6 months of 
completed antibiotic therapy. The new 
episodes were deemed as possible relapses. 
The first patient was an 85-year-old 
woman with a pacemaker. 
Echocardiography detected a vegetation on 
her pacemaker cable. Staphylococcus 
aureus was isolated from her pacemaker 
pouch. She underwent treatment with 
oxacillin for 27 days combined with an 
aminoglycoside for 7 days. Relapse 
occurred 24 days after initial antibiotic 
treatment was stopped and Staphylococcus  
 
Table 3.  A comparison of clinical data in 2971. 
episodes of blood culture negative IE divided in 
native valve and prosthesis valve infective 
endocarditis 
 
 
 
 
 
Native 
valve 
blood 
culture 
negative 
IE 
Pros-
thesis 
valve 
blood 
culture 
negative 
IE 
OR 
[95%CI] 
Number of  
episodes 1. 
240 57 - 
Age median 
[range] years 
68  
[17-89] 
66  
[25-85]  
- 
Duke criteria 
(Definite/ 
Possible) 
63 / 177 20 / 37 - 
Surgery, n (%) 
(treatment day
 median range 
[],  
33 (13), 
12  
[0-75] 
12, (21), 
10  
[0-49],  
0.6  
[0.27-1.33] 
Clinical 
and  
demo-
graphic
data 
Deaths during 
treatment n (%) 
8 (3%) 6 (11%) 0.29  
[0.09-1.08] 
1Seven episodes excluded, no data about antibiotic 
therapy).  
aureus was isolated from her blood. She 
underwent a new period of treatment with 
oxacillin (28 days) combined with an 
aminoglycoside (14 days), followed by 
oral flucloxacillin. Pacemaker extraction 
was impossible. The patient has been 
followed for three years and is still alive. 
The second patient was a 57-year-old 
woman with a valvular prosthesis. She had 
fever and heart failure. Echocardiography 
diagnosed a vegetation and an abscess 
engaging the aortic and mitral valves. She 
underwent heart valve replacement the 
same day she arrived at the hospital. There 
are no data about valve culture or 
histological examination. Antibiotic 
treatment with vancomycin and rifampicin 
continued for 56 days combined with 
aminoglycoside for 7 days. She relapsed 
18 days after the initial period of treatment 
was stopped. There are no data about blood 
culture findings or the antibiotic treatment 
during the relapse. She died 7 months later. 
 
 
 
 
5  
The third patient was a 50-year-old 
woman who had a mitral IE with 
vegetation and central nervous system 
embolism. She was treated with 
vancomycin and later teicoplanin for a 
total of 60 days. The possible relapse, 
occurred about 90 days after initial IE 
therapy was completed. She underwent 
new antibiotic treatment with vancomycin 
and teicoplanin for 60 days and cardiac 
surgery was performed with a valvular 
prosthesis insertion. The patient has been 
followed for five years without any further 
complications. 
 
Table 4. Antibiotic therapy in blood culture negative IE 
 Antibiotic 
therapy  
β-lactam  Aminoglycoside 
  
 
Aminoglycoside 
and  
β-lactam  
Vancomycin 
 
Rifampicin 
ALL CNE 
N (%), treatment (days) 
median, range []  
297 (100) 
28 [1-101]  
261 (88) 
 28 [2-77]  
249 (84) 
14 [2-63]  
232 (78) 
14 [1-49]  
81 (27)  
21 [2-83]  
12 (4)  
27 [6-56]  
NATIVE VALVE CNE 
N (%), treatment (days) 
median, range []  
240 (100), 
28 [1-101]  
216 (90),  
28 [2-77]  
201, (84),  
14 [2-56]  
192 (80), 
 14 [1-40]  
57 (24),  
15 [2-83]  
8 (3), 
 21 [6-43]  
PROSTHETIC VALVE 
CNE,  N (%), treatment 
(days) median, range []  
57, (100), 
 28 [1-89]  
45 (79) 
25 [2-80]  
48 (84),  
14 [3-63],  
40 (70), 
 14 [1-27]  
24, (42), 
 30 [2-56]  
4 (7)  
42 [21-56]  
Abbreviations: β-lactam: Penicillin G, ampicillin, oxacillin, cephalosporin and carbapenem, blood culture 
negative IE (CNE). 
 
Table 5. Fatal outcome in eight episodes of blood culture negative native valve endocarditis with special 
attention to antibiotic therapy 
  
ANTIBIOTIC TREATMENT (DAYS) 
 Death 
day 
Age, 
years 
sex 
 
Duke 
criteria 
Echo-
cardiography  
 
Affected 
valve  
 
Post- 
mortem 
examination, 
cause of death 
β-lactam  Amino- 
glycoside 
 
β-lactam 
and 
amino- 
glycoside  
Vanco- 
mycin  
All 
antibiotics 
 
 
1 
 
21 
 
75 F 
 
D 
TTE, TEE. 
Vegetation, 
pericardial 
effusion 
 
AO 
Not done, 
myocardial 
infarctation 
suspected 
 
21 
 
16 
 
16 
 
0 
 
21 
 
2 
 
21 
 
81 F 
 
D 
TTE. 
Vegetation 
 
MI 
 
IE 
 
21 
 
10 
 
10 
 
0 
 
21 
 
3 
 
17 
 
78 F 
 
D 
 
Not done 
 
 
AO 
IE. Diagnosed  
as pneumonia 
ante mortem 
 
17 
 
0 
 
0 
 
0 
 
17 
 
4 
 
15 
 
52 F 
 
D 
 
TEE. 
Vegetation 
 
AO 
 
Yes, multi 
organ failure 
 
Number 
of days 
unknown 
 
Number 
of days 
unknown 
 
Number 
of days 
unknown 
 
0 
 
0 
 
5 
 
5 
 
79 F 
 
D 
TTE, TEE 
Difficult to 
visualize 
structures  
 
AO 
Yes: sepsis, 
hepatocellular 
cancer 
 
5 
 
0 
 
0 
 
0 
 
5 
 
6 
 
20 
 
46 F 
 
D 
 
TTE. 
Vegetation 
 
MI 
 
Yes. Heart 
rupture, IVDU 
 
20 
 
11 
 
11 
 
0 
 
20 
 
7 
 
57 
 
42 F 
 
D 
TEE. 
Vegetation, 
ventricular 
septum defect 
 
MI 
Yes, multi-
organ failure 
(Streptococcus 
anginosus in 
pleural fluid 
 
17 
 
0 
 
0 
 
2 
 
19 
 
8 
 
17 
 
76 M 
 
P 
TTE, TEE 
Suspected 
pace maker 
vegetation  
 
TRI 
 
Yes. Result 
unknown 
 
15 
 
0 
 
0 
 
0 
 
15 
Abbreviations: Female (F), Male (M), Definite (D), Possible (P), Aortic valve (AO), mitral valve (MI), tricuspid valve (TRI).  
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Table 6. Fatal outcome in six episodes of blood culture negative prosthetic valve endocarditis with special 
attention to antibiotic therapy  
 
 Antibiotic treatment (days) 
No. DEATH  DAY 
Age 
(YS)  
sex  
Duke  
ECHOCARDIO- 
GRAPHY   
 
Affected 
valve 
Postmortem 
examination, 
cause of 
death  
β-
lactam  
Amino- 
glycoside 
 
β-lactam 
and 
amino- 
glycoside 
combined  
Vanco- 
mycin 
 All 
antibiotics 
 
1 24 75 F P 
TTE, TEE 
Vegetation 
valvular 
dehiscence 
MI Not done, heart failure 0 3 0 24 24 
2 19  71 F D 
TEE 
Vegetation 
AO and 
MI 
Cerebral 
bleeding 19 16 16 1 20 
3 23 81 F P 
TTE 
Vegetation, heart 
failure  
 AO Not done, not described 24 4 4  24 
4 21 58  M D 
TEE 
Vegetation  MI 
Not done, 
renal failure 22 12 12 0 22 
5 17 80 F D TTE, TEE Vegetation  MI  
Not done, 
gastro-
intestinal 
bleeding, 
pulmonary 
embolism 
14 0 0 0 14 
 11 81 M P 
TTE, TEE 
Vegetation, 
valvular stenosis 
 MI  No data 9 8 8  2 11 
Abbreviations: Female (F), Male (M), Years (YS), Definite (D), Possible (P), Aortic valve (AO), mitral valve (MI), tricuspid valve (TRI).  
 
  
Discussion 
The proportion of CNE found (12%) is less 
than in an earlier prospective study of CNE 
from Western Sweden (5). The prevalence 
of CNE was approximately 20% in all 
episodes of IE in that study. This may be 
due to selection bias, since the present 
study is based on data from reporting 
doctors and CPE episodes may have been 
reported to a higher degree than CNE 
episodes.  
The Duke possible group is 
heterogeneous; CNE patients who would 
be classified in the possible Duke criteria 
group in a prospective study may have 
been given other diagnoses such as heart 
failure or pneumonia. (7).  Also there are 
opportunities for misclassification of CNE 
with the Duke criteria, diagnosing obvious 
definite cases as possible (9).  
The absence of positive blood cultures 
may be one reason not to perform an 
echocardiography. Although IE is not a 
self-limiting disease, short treatment (four 
days or less) with intravenous antibiotics 
may cure it, which the Duke criteria 
consider when differentiating between the 
“Possible” and “Reject” groups. The low 
proportion of Duke definite CNE episodes 
(4 %) of all Duke definite IE episodes 
corresponds to our previous findings (5), 
and is probably attributable to 
underestimation of the “real” proportion of 
IE with the classification system (5). 
Mortality in all IE-episodes during the 
study period was 10.3 %. The mortality is 
low as compared with recently published 
studies of IE; 16% France (1999), 24%, 
Argentina (2002), 14% Northern Italy 
(2000-1), 26% Minnesota US (1970-2000), 
(10-13)  
Methicillin resistant Staphylococcus 
aureus still has a low prevalence in 
Sweden and nearly all patients with IE are 
treated at specialized Infectious Diseases 
Departments.  These factors may 
contribute to the estimated low mortality.  
Data from CNE and CPE episodes are in 
good agreement. The absence of positive 
blood cultures explains the low proportion 
 
 
 
 
7  
of Duke definite episodes in the CNE 
group (27%) as compared with the CPE 
group (85%) (3, 5, 14, 15) as blood culture 
findings are one of the cornerstones of the 
Duke criteria (7). There were fewer IVDU 
in the CNE group than in the CPE group 
(3% vs. 12%). Tricuspid IE was also less 
common (5% vs. 12%). Pacemaker 
endocarditis with right-sided IE has been 
associated with CNE but we have not been 
able to test this hypothesis since the CRF 
did not contain this information. 
Vascular phenomena were less common 
in CNE patients than in CPE patients (21 
vs. 35%). This finding corresponds to other 
studies (5, 14).   
The aortic valves were more often 
affected in CNE patients than in CPE 
patients (50% vs. 38%). Also this is in 
accordance with findings by others (15, 
16). We suggest that the hemodynamic 
influence of a diseased aortic valve makes 
the clinicians to order an echocardiography 
in spite the fact that the blood cultures are 
negative. 
It is well known that patients who have 
received antibiotic treatment before blood 
cultures are often found to have CNE (3-5, 
17). Data on antibiotic treatment before 
admission were not reliable enough to 
draw any conclusions about this. 
False positive echocardiographic 
findings such as nodular thickening, non-
oscillating tissue and uninfected thrombi 
may be difficult to differentiate from IE 
vegetation (18) and might to some extent 
contribute to increase the group of CNE 
patients. 
Surgery was performed in 16% of the 
CNE episodes as compared to 21 % in the 
CPE episodes.  This corresponds well to 
the findings in a previous study with 
surgery in 15% of the episodes (5). 
Mortality was lower in the CNE than the 
CPE group (5% vs. 11%). The relatively 
low mortality and low prevalence of acute 
valvular surgery in CNE patients may 
indicate that CNE in Sweden might be a 
milder variant of IE. Preparedness for early 
parenteral antibiotic treatment may have 
affected the positive outcome. It is also of 
importance to point out that there were no 
reported episodes of Q-fever or infection 
with Bartonella, which, if present could 
have contributed to a worse outcome.  
There was a fatal outcome in 9% of the 
women with CNE episodes vs. 2% in 
males, aOR 5.5. The increased odds ratio 
indicates that treatment and diagnostic 
procedures for women with CNE need 
improvement. 
The proportion of PVE was nearly the 
same in the CNE and the CPE groups (19 
% vs. 18%). The data forms did not 
include questions about how long the PVE 
patients had had their heart valve 
prostheses, a factor that influences which 
microorganisms most frequently infect the 
valve. Seventy-eight percent of all patients 
got combination therapy with an 
aminoglycoside and a beta-lactam 
antibiotic, but fewer patients were treated 
with this combination in the PVE group 
(70%). Vancomycin treatment was 
predominant in the PVE group (42% vs. 
24%). Only twelve patients received 
treatment with rifampicin four (7%) PVE 
and eight (3%) NVE patients. The impact 
of rifampicin treatment in CNE warrants 
further studies. The higher mortality in 
patients without aminoglycoside therapy 
(p=0.03) supports the inclusion of 
aminoglycoside in the treatment regimen 
of CNE, as suggested in recently published 
guidelines from the US (19) and also from 
Europe (8, 20). This is important, as the 
impact of aminoglycoside treatment in IE 
has attracted a great deal of attention in 
recent years (21, 22).  
We used the term possible relapse as a 
new event of IE during the 6 months after 
completed IE therapy.  If confirmational 
testing by molecular analysis is not 
performed, the terms relapse and 
reinfection are inadequate (23).  It is 
obvious that the term reinfection is 
difficult to use in patients with CNE.  
In conclusion, in a ten-year survey of IE 
in Sweden the proportion of CNE in the 
reported episodes treated as IE was 12%. 
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Mortality in IE during the studied ten-year 
period was low (10.3%) and it was even 
lower (5%) in CNE. There were no great 
differences in demographic or other 
predisposing factors between CNE and CPE. 
Patients with CNE who received 
aminoglycoside therapy survived more 
frequently than CNE patients who did not 
receive this therapy. The study indicates that 
aminoglycosides should be used in the 
treatment of CNE. 
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